

P1 1030338

REC'D 0:1 JUL 2003

WIPO PCT

# THE UNITED STATES OF AMERICA

**TO ALL TO WHOM THESE PRESENTS SHALL COME:**

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office

June 25, 2003

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/390,102

FILING DATE: June 19, 2002

RELATED PCT APPLICATION NUMBER: PCT/US03/16207

By Authority of the  
COMMISSIONER OF PATENTS AND TRADEMARKS



*M. Tarver*

M. TARVER  
Certifying Officer

**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

**BEST AVAILABLE COPY**

06/19/02  
JC966 U.S. PTO

06-21-02

7/1/02

Modified PTO/SB/16 (6-95)

Approved for use through 04/11/98. OMB 0651-0037

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

# PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c)

Docket Number **P-14844**

Type a plus sign (+) inside this box -> **+**

## INVENTOR(s)/APPLICANT(s)

LAST NAME	FIRST NAME	MIDDLE NAME	RESIDENCE (CITY AND EITHER STATE OR FOREIGN COUNTRY)
Ferritto	Rafael	Crespo	Spain
Martin	Jose	Alfredo	Spain
Martin-Ortega Finger	Marie	Dolores	Spain
Rojo	Isabel	Garcia	Spain
Shen	Quan Rong		Fishers, Indiana
Warshawsky	Alan	M	Carmel, Indiana
Xu	Yanping		Fishers, Indiana

11002 U.S. PTO  
60/390102

06/19/02

## TITLE OF THE INVENTION (280 characters max)

**PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONISTS**

## CORRESPONDENCE ADDRESS

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288



**25885**

PATENT TRADEMARK OFFICE

STATE **IN** ZIP CODE **46206-6288** COUNTRY **USA**

## ENCLOSED APPLICATION PARTS (check all that apply)

<input checked="" type="checkbox"/> Specification	Number of pages <b>171</b>	<input type="checkbox"/> Small Entity Statement
<input type="checkbox"/> Drawing(s)	Number of Sheets <b></b>	<input type="checkbox"/> Other (Specify) <b></b>

## METHOD OF PAYMENT (check one)

<input type="checkbox"/> A check or money order is enclosed to cover the Provisional filing fees	PROVISIONAL FILING FEE AMOUNT (\$)	<b>\$160.00</b>
<input checked="" type="checkbox"/> The Assistant Commissioner is hereby authorized to charge filing fees and credit Deposit Account Number: <b>05-0840</b>		

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No.

☐ Yes, the name of the U.S. Government agency and the Government contract number are:

Respectfully submitted,  
SIGNATURE MaCharri Vorndran-Jones

Date **06/19/02**

TYPED or PRINTED NAME **MaCharri Vorndran-Jones**

REGISTRATION NO. (if appropriate) **36,711**

☐ Additional inventors are being named on separately numbered sheets attached hereto

## PROVISIONAL APPLICATION FOR PATENT FILING ONLY

"Express Mail" mailing label number **EL342550276US** Date of Deposit **June 19, 2002**  
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Arlington, VA, 22202.

Printed Name **Queen Thomas**

Signature Queen Thomas

## PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONISTS

## BACKGROUND OF THE INVENTION

5 Peroxisome Proliferator Activated Receptors (PPARs) are members of the nuclear hormone receptor super family, which are ligand-activated transcription factors regulating gene expression. Various subtypes of PPARs have been discovered. These include PPAR $\alpha$ , NUC1, PPAR $\gamma$  and PPAR $\delta$ .

10 The PPAR $\alpha$  receptor subtypes are reported to be activated by medium and long-chain fatty acids. They are involved in stimulating beta-oxidation of fatty acids and with the activity of fibrates which reportedly produce a substantial reduction in plasma triglycerides and moderate reduction in low density lipoprotein (LDL) cholesterol.

15 PPAR $\alpha$ , PPAR $\gamma$  and PPAR $\delta$  receptors have been implicated in diabetes mellitus, cardiovascular disease, obesity, Syndrome X and gastrointestinal disease, such as, inflammatory bowel disease. Syndrome X is the combination of symptoms which include hyperinsulemia combined with hypertension, elevated body weight, elevated triglycerides and elevated LDL.

20 Current PPAR agonist treatment for Syndrome X relates to the use of thiazolidinediones (TZDs) or other insulin sensitivity enhancers (ISEs). TZDs are a class of PPAR gamma agonists which have been shown to increase the


25	"Express Mail" mailing label number	EL342550276US
	Date of Deposit	June 19, 2002
30	I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Arlington, VA 22202	
35	GUEN Thomas	Guen Thomas
	Printed Name	Signature

sensitivity of insulin sensitive cells. Increasing insulin sensitivity rather than the amount of insulin in the blood reduces the likelihood of hypoglycemic coma. However, TZDs and ISEs are often associated undesirable side effects and improved clinical profiles are desired. Therefore, a need exists for new pharmaceutical agents having a desired pharmacological profile and desired clinical effect.

## SUMMARY OF THE INVENTION

An embodiment of the present invention is directed toward compounds represented by the following structural formula:

Formula I



- (a) R1 is selected from the group consisting of hydrogen, substituted or unsubstituted group selected from C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, aryl-C<sub>0-4</sub>-alkyl, heteroaryl-C<sub>0-4</sub>-alkyl, aminoC<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkylaryl-C<sub>0-2</sub>-alkyl, arylheteroC<sub>1</sub>-C<sub>8</sub>alkyl, -CHC(O)C<sub>1</sub>-C<sub>4</sub>alkoxy; C<sub>0-4</sub>-alkyl-C(O)heteroC<sub>1</sub>-C<sub>8</sub>alkyl, and -CH<sub>2</sub>-C(O)-R15-R16, wherein R15 is O or NH and R16 is optionally substituted benzyl;
- (b) R2 is selected from the group consisting of substituted or unsubstituted group selected

from C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, aryl-C<sub>0</sub>-  
4-alkyl, heteroaryl-C<sub>0</sub>-4-alkyl, aminoC<sub>1</sub>-  
C<sub>4</sub>alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkylaryl-C<sub>0</sub>-2-alkyl,  
arylheteroC<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>0</sub>-4-alkyl-C(O)heteroC<sub>1</sub>-  
C<sub>8</sub>alkyl, and -CH<sub>2</sub>-C(O)-R<sub>15</sub>-R<sub>16</sub>, wherein R<sub>15</sub>  
is O or NH and R<sub>16</sub> is optionally substituted  
benzyl;

- (c) R<sub>1</sub> and R<sub>2</sub> together may form a substituted or  
unsubstituted heterocyclic ring;
- (d) E is selected from the group consisting of  
C(R<sub>3</sub>)(R<sub>4</sub>)A, and a substituted or  
unsubstituted selected from the group  
consisting of (CH<sub>2</sub>)<sub>n</sub> COOR<sub>13</sub>, aryl-C<sub>0</sub>-4-alkyl,  
thio-C<sub>1</sub>-4-alkyl, thioaryl, C<sub>1</sub>-4alkoxyaryl,  
C<sub>1</sub>-4alkoxyC<sub>1</sub>-4alkyl, aminoaryl, and aminoC<sub>1</sub>-  
4alkyl;
- (e) n and m are each independently selected from  
the group consisting of 0, 1, 2 and 3;
- (f) A is an functional group selected from the  
group consisting of (CH<sub>2</sub>)<sub>m</sub> COOR<sub>14</sub>, C<sub>1</sub>-  
C<sub>3</sub>alkylnitrile, carboxamide, substituted or  
unsubstituted sulfonamide, substituted or  
unsubstituted acylsulfonamide and substituted  
or unsubstituted tetrazole;
- (g) R<sub>3</sub> is H, saturated or unsaturated C<sub>1</sub>-C<sub>5</sub>  
alkyl, C<sub>1</sub>-C<sub>5</sub> alkoxy;
- (h) R<sub>4</sub> is H, halo, a substituted or  
unsubstituted group selected from C<sub>1</sub>-C<sub>5</sub>  
alkyl, C<sub>1</sub>-C<sub>5</sub> alkoxy, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, aryl  
C<sub>0</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-4alkoxyaryl, and phenyl, or

R3 and R4 are combined to form a C<sub>3</sub>-C<sub>6</sub> cycloalkyl;

5

- (i) R5 and R6 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted group selected from C<sub>1</sub>-C<sub>8</sub> alkyl, aryl-C<sub>0-4</sub>-alkyl, heteroaryl-C<sub>0-4</sub>-alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkylaryl-C<sub>0-2</sub>-alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl-C<sub>0-2</sub>-alkyl, and -CH<sub>2</sub>-C(O)-R17-R18;

10

- (j) R17 and R18 are each independently selected from C<sub>1</sub>-C<sub>8</sub> alkyl, aryl-C<sub>0-4</sub>-alkyl, heteroaryl-C<sub>0-4</sub>-alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkylaryl-C<sub>0-2</sub>-alkyl, and C<sub>3</sub>-C<sub>6</sub> cycloalkyl-C<sub>0-2</sub>-alkyl;


15

- (k) R13 and R14 are each independently selected from the group consisting of hydrogen, optionally substituted C1-C4alkyl and optionally substituted arylmethyl; and

pharmaceutically acceptable salts thereof.

20

Another embodiment of the present invention is a compound of Formula II:




25

wherein R19 is selected from the group consisting of hydrogen, a substituted or unsubstituted group selected from the group consisting of C1-C4alkyl, aryl, and arylmethyl;

and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are as defined above in Formula I.


Another embodiment of the present invention is a  
5 compound of Formula III:



wherein R19 is selected from the group consisting of hydrogen, a substituted or unsubstituted group selected from the group consisting of C1-C4alkyl, aryl, and arylmethyl;


and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are as defined above in Formula I.

Another embodiment of this invention is a compound and pharmaceutically acceptable salts of Structural Formula:




wherein R11 is selected from the group consisting of here\*.

20 Another preferred embodiment is a compound and pharmaceutically acceptable salts of Structural Formula:



wherein R12 is here\*.

Another embodiment is a compound of the formula:



In another feature of this invention, a compound claimed herein is radiolabeled.

In one embodiment, the present invention also relates to pharmaceutical compositions which comprising at least one compound of the present invention, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

In another embodiment, the present invention relates to a method of modulating a PPAR alpha receptor by contacting the receptor with at least one compound represented by Structural Formula I, and/or pharmaceutically acceptable salts thereof.

In another embodiment, the present invention relates to a method of modulating a PPAR gamma receptor by contacting the receptor with at least one compound represented by

50390102-061907

5

10

15

20

Structural Formula I, and/or pharmaceutically acceptable salts thereof.

In another embodiment, the present invention relates to a method of modulating a PPAR delta receptor by contacting  
5 the receptor with at least one compound represented by Structural Formula I, and/or a pharmaceutically acceptable salt thereof.

In another embodiment, the present invention relates to a method of modulating a PPAR alpha receptor and a PPAR  
10 gamma receptor by contacting the receptor with at least one compound represented by Structural Formula I, and/or pharmaceutically acceptable salts thereof.

50390102.061902  
20 The compounds of the present invention and pharmaceutically acceptable salts thereof can be effective in treating and, in patients susceptible thereto, preventing, Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagulopathy, hypertension, atherosclerosis, and other disorders related to Syndrome X and cardiovascular diseases. In addition, the compounds are  
20 expected to be associated with fewer side effects than compounds currently used to treat these conditions. Further, compounds of this invention can be useful for lowering fibrinogen, increasing HDL levels, treating renal disease, controlling desirable weight, treating  
25 demyelinating diseases, treating certain viral infections, and treating liver disease.

#### DETAILED DESCRIPTION OF THE INVENTION

The terms used to describe the instant invention have  
30 the following meanings herein.

As used herein, "alkyl" groups include straight chained and/or branched hydrocarbons, which are completely saturated.

As used herein, "alkylene" linker is an optionally  
5 unsaturated C<sub>1</sub>-C<sub>5</sub> straight or branched chain hydrocarbon group.

"Cycloalkyl" groups, as used herein, include cyclic hydrocarbons, which are partially or completely saturated. It can be preferred that the cycloalkyl groups are  
10 completely saturated. Such cycloalkyl includes, but is not limited to cyclopropyl, cyclopentyl, cyclohexyl, and the like.

As used herein, "aryl" groups include carbocyclic aromatic ring systems (e.g. phenyl), fused polycyclic aromatic ring systems (e.g. naphthyl and anthracenyl) and aromatic ring systems fused to carbocyclic non-aromatic ring systems (e.g., 1,2,3,4-tetrahydronaphthyl and benzodioxyl). A preferred aryl group can be phenyl.

The term "cycloalkyaryl" means that a cycloalkyl group  
15 is fused with an aryl group to form a bicyclic substituent. Cycloalkylarylalkyl means that the fused bicyclic cycloalkylaryl is linked to the base molecule through an alkyl linker.

As used herein, "arylalkyl" means that the aryl group  
25 is linked to the point of attachment through an alkyl linker. The term "aryl-C<sub>0</sub>alkyl" means that the aryl group is directly linked at the point of attachment through a bond.

The term "halo" means Cl, F, Br, and I. A preferred  
30 halo can be Cl. A preferred halo can be F.


As used herein, "heteroaryl" groups include carbocyclic aromatic ring systems wherein at least one carbon of the

50390102.061900  
1205120.20106209

aryl group is replaced by at least one independently selected heteroatom, such as nitrogen, oxygen or sulfur (e.g. pyridinyl and the like), fused polycyclic aromatic ring systems having at least one heteroatom replacing a carbon from the ring and aromatic ring systems fused to carbocyclic non-aromatic ring systems having at least one heteroatom replacing a carbon atom from the ring. A preferred heteroaryl group can be thiophenyl, pyridinyl, piperidinyl, pyrazinyl, and the like. Another preferred heteroaryl group can be oxazole, thiazole, and the like.


As used herein, "arylalkyl" means that the aryl group is linked to the point of attachment through an alkyl linker. The term "aryl-C<sub>0</sub>alkyl" means that the aryl group is directly linked at the point of attachment through a bond.

Heterocyclic group, as used herein, is a ring system having at least one heteroatom such as nitrogen, sulfur or oxygen. Heterocyclic groups include benzofuranyl, benzothiazolyl, benzothienyl, isoquinolyl, isoxazolyl, morpholino, oxadiazolyl, pyridyl, pyrimidinyl, pyrrolyl, quinolyl, tetrahydropyranyl and thienyl. Preferred



heterocyclic rings may be and/or

The term "heterocycloalkylaryl" means that a heterocyclic group is fused to an aryl group to form the substituent. Such groups include, but are in no way limited



5 The term "thioaryl" means that the aryl ring has at least one carbon atom replaced by a sulfur atom. Such thioaryl groups include, but are not limited to thiophenyl, and the like.

10 The term "alkoxyaryl" means that the aryl group is attached to the base molecule through an alkoxy linker. The term "alkoxyalkyl" means that the alkyl chain has one carbon replaced by an oxygen atom. The term "aminoaryl" means that the aryl group is linked to the base molecule through an amino group. The term "aminoalkyl" means that the alkyl chain is attached to the base molecule through an amino group. The term "alkylnitrile" means that the nitrile group is attached to the base molecule through an alkyl linker.

50390102-05190120

15 As used herein, the term, "arylheteroC<sub>1</sub>-C<sub>8</sub>alkyl" means that the aryl group is attached to the base nucleus through a C<sub>1</sub>-C<sub>8</sub>alkyl group in which one of the carbon atoms of the alkyl group is replaced with a heteroatom selected from the group consisting of S, O, and N. One embodiment is when the heteroatom is an S and the aryl is an optionally substituted phenyl. Another embodiment is when the heteroatom is an O and the aryl is an optionally substituted phenyl. Another embodiment is when the heteroatom is a N and the aryl is an optionally substituted phenyl.

25 As used herein, the term, "C<sub>0-4</sub>-alkyl-C(O)heteroC<sub>1</sub>-C<sub>8</sub>alkyl" means that the heteroC<sub>1</sub>-C<sub>8</sub>alkyl group, wherein one of the carbon atoms of the alkyl group is replaced with a heteroatom selected from the group consisting of S, O and N, is linked to the base nucleus through a C<sub>0-4</sub>-alkylC(O) group. Embodiments include, but are not limited to when the  
30 heteroalkyl is methoxy, ethoxy, propoxy, and the like.

As used herein, the term, "substituted aryl substituent", "substituted -C(O)aryl substituent" and "substituted alkylaryl substituent" means that the aryl or alkylaryl group is further substituted with one or more substituents independently selected from the group consisting of halo, C1-C5 alkyl, C1-C5 haloalkyl, C1-C5 alkoxy, and -C(O)C1-C5alkyl,

As used herein the term "substituted C1-C5 alkylbiaryl" means that the two aryl groups are each independently optionally substituted with one or more substituents independently selected from the group consisting of halo, C1-C8alkyl,

As used herein, the term "substituted C1-C5 alkylaryl" and "substituted arylmethyl" means that the aryl group is substituted with one or more substituents independently selected from the group consisting of halo, C1-C8alkyl, aryl, haloalkyl, trihaloalkyl, alkoxy, and arylalkyl.

Examples of suitable substituents when said R1 or R2 is substituted alkyl, aryl, aryl alkyl, heteroarylalkyl, aminoalkyl, arylheteroC1-C8alkyl, cycloalkyl, cycloalkylarylalkyl, arylheteroalkyl, alkylC(O)heteroalkyl, -CH2C(O)R15R16, and R1 and R2 form a cyclic ring, are one or more independently selected from the group consisting of C1-C5 alkyl, C3-C6 cycloalkyl, C1-C5 haloalkyl, C1-C5 alkoxy, aryloxy, haloC1-C3alkyl, halo, aryl, -C(O)C1-C5alkyl, -C(O)-aryl, substituted -C(O)aryl substituent, haloC1-C5alkyloxy, substituted aryl substituent, C1-C5 alkylaryl, substituted alkylaryl substituent, C1-C5 alkylbiaryl, substituted C1-C5 alkylbiaryl, and when R1 and R2 form a cyclic ring, such substituted or unsubstituted ring may be fused with another cyclic or aryl group to form a bicyclic group. When R1 or

50390102-061902

R2 is substituted, it can be preferred that there are from 1 to 3 substituents on said R1 or R2.

Suitable substituents for R13 and R14 when R13 and/or R14 is optionally substituted "C1-C4 alkyl" include for example, C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>1</sub>-C<sub>5</sub> haloalkyl, C<sub>1</sub>-C<sub>5</sub> alkoxy, aryloxy, halo, aryl, -C(O)C<sub>1</sub>-C<sub>5</sub>alkyl, -C(O)-aryl, substituted -C(O)aryl substituent, haloC<sub>1</sub>-C<sub>5</sub>alkyloxy, substituted aryl substituent, C<sub>1</sub>-C<sub>5</sub> alkylaryl, substituted alkylaryl substituent, C<sub>1</sub>-C<sub>5</sub> alkylbiaryl, and substituted C<sub>1</sub>-C<sub>5</sub> alkylbiaryl.

Suitable substituents for E when said E is selected from the group consisting of (CH<sub>2</sub>)<sub>n</sub> COOR<sub>13</sub>, aryl-C<sub>0-4</sub>-alkyl, thio-C<sub>1-4</sub>-alkyl, thioaryl, C<sub>1-4</sub>alkoxyaryl, C<sub>1-4</sub>alkoxyC<sub>1-4</sub>alkyl, aminoaryl, and aminoC<sub>1-4</sub>alkyl include, for example, C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>1</sub>-C<sub>5</sub> alkoxy, C<sub>1</sub>-C<sub>5</sub> haloalkyl, C<sub>1</sub>-C<sub>5</sub> haloalkoxy, nitro, cyano, CHO, hydroxyl, C<sub>1</sub>-C<sub>4</sub> alkanolic acid phenyl, aryloxy, SO<sub>2</sub>R<sub>7</sub>, SR<sub>7</sub>, benzyloxy, alkylcarboxamido and COOH. R<sub>7</sub> is an alkyl or a haloalkyl. When E is substituted, it is preferred that there are from 1-3 substitutions on said E group.

Examples of suitable substituents for a substituted C<sub>1</sub>-C<sub>3</sub> alkylene, include one or more independently selected from C<sub>1</sub>-C<sub>6</sub>alkyl, oxo, aryl C<sub>0</sub>-C<sub>3</sub>alkyl, C<sub>1</sub>-C<sub>3</sub>alkoxy, hydroxy, and halo. When the alkylene is substituted it is preferred that there are from 1-3 independent substitutions.

Examples of suitable substituents for an "optionally substituted C<sub>2</sub>-C<sub>5</sub> alkylene linker", include one or more independently selected from the group consisting of C<sub>1</sub>-C<sub>6</sub>alkyl, oxo, substituted or unsubstituted arylC<sub>0</sub>-C<sub>3</sub>alkyl, C<sub>1</sub>-C<sub>3</sub>alkoxy, hydroxy, C<sub>3</sub>-C<sub>6</sub>cycloalkyl and halo. When the

alkylene linker is substituted, it is preferred that there are from one to three independent substitutions.

Examples of suitable substituents for A groups, wherein the A is a sulfonamide, include one or more independently selected from C1-C4 alkyl, C1-C4 haloalkyl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted aryl. When the A group is substituted, it is preferred that there are from 1-3 independent substitutions on the A group.

Examples of suitable substituents for A groups, wherein A is acylsulfonamide and tetrazole include, for example, one or more independently selected from C1-C4 alkyl, C1-C4 haloalkyl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted aryl.

Suitable substituents for R4 wherein R4 is selected from the group consisting of C1-C5 alkyl, C1-C5 alkoxy, C3-C6 cycloalkyl, aryl C0-C4 alkyl, C1-4alkoxyaryl, and phenyl, include, for example C1-C5 alkyl, C1-C5 alkoxy, halo, C1-C5 haloalkyl, C1-C5 haloalkoxy, nitro, cyano, CHO, hydroxyl, C1-C4 alkanoic acid, phenyl, aryloxy, SO<sub>2</sub>R7, SR7, benzyloxy, alkylcarboxamido and COOH. R7 is an alkyl or a haloalkyl. When R4 is substituted, it is preferred that there are from 1-4 independent substitutions on the R4 group.

Suitable substituents for R5, R6, R17, and/or R18 wherein said R5, R6, R17, and/or R18 are each independently selected from the group consisting of C1-C8 alkyl, aryl-C0-4-alkyl, heteroaryl-C0-4-alkyl, C3-C6 cycloalkylaryl-C0-2-alkyl, C3-C6 cycloalkyl-C0-2-alkyl, and/or -CH<sub>2</sub>-C(O)-R17-R18, include for example, substituents independently selected from C1-C5 alkyl, C1-C5 alkoxy, halo, C1-C5 haloalkyl, C1-C5 haloalkoxy, nitro, cyano, CHO, hydroxyl, C1-C4 alkanoic acid, phenyl, aryloxy, SO<sub>2</sub>R7, SR7, benzyloxy, alkylcarboxamido and COOH. R7 is an alkyl or a haloalkyl.

When said R5, R6, R17, and/or R18 is substituted, it can be preferred that said R5, R6, R17, and/or R18 group has from 1-4 independently selected substituents.

As used herein the term "C1-C4 haloalkyl" means that  
5 the carbon atoms of the alkyl may be substituted with one or more halogens. For example, but not limited to, CF<sub>3</sub>, C<sub>2</sub>F<sub>5</sub>, C<sub>2</sub>F<sub>3</sub> and the like.

Preferably, for the compounds of the present invention, represented by Structural Formula I, and with their  
10 respective pharmaceutical compositions, X contains an oxygen.

60390102-051900  
205190-2970600  
20  
The compounds of Structural Formula I may contain one or more chiral centers, and exist in different optically active forms. When compounds of Structural Formula I  
5 contain one chiral center, the compounds exist in two enantiomeric forms and the present invention includes both enantiomers and mixtures of enantiomers, such as racemic mixtures. The enantiomers may be resolved by methods known to those skilled in the art, for example by formation of diastereoisomeric salts which may be separated, for example,  
10 by crystallization; formation of diastereoisomeric derivatives or complexes which may be separated, for example, by crystallization, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an  
25 enantiomer-specific reagent, for example enzymatic esterification; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support for example silica with a bound chiral ligand or in the presence of a chiral solvent. It will be appreciated that where the  
30 desired enantiomer is converted into another chemical entity by one of the separation procedures described above, a further step is required to liberate the desired

enantiomeric form. Alternatively, specific enantiomers may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer into the other by asymmetric transformation.

When a compound represented by Structural Formula I has more than one chiral substituent it may exist in diastereoisomeric forms. The diastereoisomeric pairs may be separated by methods known to those skilled in the art, for example chromatography or crystallization and the individual enantiomers within each pair may be separated as described above. The present invention includes each diastereoisomer of compounds of Structural Formula I and mixtures thereof.

Certain compounds of Structural Formula I may exist in different stable conformational forms which may be separable. Torsional asymmetry due to restricted rotation about an asymmetric single bond, for example because of steric hindrance or ring strain, may permit separation of different conformers. The present invention includes each conformational isomer of compounds of Structural Formula I and mixtures thereof.

Certain compounds of Structural Formula I may exist in zwitterionic form and the present invention includes each zwitterionic form of compounds of Structural Formula I and mixtures thereof.

"Pharmaceutically-acceptable salt" refers to salts of the compounds of the Structural Formula I that are substantially non-toxic to mammals. Typical pharmaceutically-acceptable salts include those salts prepared by reaction of the compounds of the present invention with a mineral or organic acid or an organic or inorganic base. Such salts are known as base addition

salts, respectively. It should be recognized that the particular counterion forming a part of any salt of this invention is not of a critical nature, so long as the salt as a whole is pharmaceutically-acceptable and as long as the counterion does not contribute undesired qualities to the salt as a whole.

By virtue of its acidic moiety, a compound of Structural Formula I forms salts with pharmaceutically acceptable bases. Some examples of base addition salts include metal salts such as aluminum; alkali metal salts such as lithium, sodium or potassium; and alkaline earth metal salts such as calcium and magnesium; and ammonium or substituted ammonium salts. Examples of substituted ammonium salts include, for instance, those with lower alkylamines such as trimethylamine, triethylamine; hydroxyalkylamines such as 2-hydroxyethylamine, bis-(2-hydroxyethyl)-amine or tri-(2-hydroxyethyl)-amine, cycloalkylamines such as bicyclohexylamine or dibenzylpiperidine, N-benzyl- $\beta$ -phenethylamine, dehydroabietylamine, N,N'-bisdehydro-abietylamine, glucamine, N-methylglucamine; bases of the pyridine type such as pyridine, collidine, quinine or quinoline; and salts of basic amino acids such as lysine and arginine.

These salts may be prepared by methods known to those skilled in the art.

In addition, it is generally not desirable to formulate pharmaceuticals containing substantial amounts of organic solvent (e.g., ethyl acetate) due to potential solvent toxicity to the recipient thereof and changes in potency of the pharmaceutical as a function of the solvent.

The term, "active ingredient" means the compounds generically described by Structural Formula I as well as the salts of such compounds.

5 The term "pharmaceutically acceptable" means that the carrier, diluent, excipients and salt must be compatible with the other ingredients of the composition. Pharmaceutical compositions of the present invention are prepared by procedures known in the art using well-known and readily available ingredients.

10 "Preventing" refers to reducing the likelihood that the recipient will incur or develop any of the pathological conditions described herein. It is preferred that the recipient is thought to be susceptible to said condition.

15 "Treating" refers to mediating a disease or condition and preventing, or mitigating, its further progression or ameliorate the symptoms associated with the disease or condition.

20 "Pharmaceutically-effective amount" means that amount of a compound, or of its salt thereof, that will elicit the biological or medical response of a tissue, system, or mammal. Such an amount can be administered prophylactically to a patient thought to be susceptible to development of a disease or condition. Such amount when administered prophylactically to a patient can also be effective to  
25 prevent or lessen the severity of the mediated condition. Such an amount is intended to include an amount which is sufficient to modulate a PPAR alpha receptor or to prevent or mediate a disease or condition. Conditions prevented or treated by PPAR $\alpha$  receptors include diabetes mellitus,  
30 cardiovascular disease, Syndrome X, obesity and gastrointestinal disease.

A "mammal" is an individual animal that is a member of the taxonomic class Mammalia. The class Mammalia includes humans, monkeys, chimpanzees, gorillas, cattle, swine, horses, sheep, dogs, cats, mice, and rats.

5 Administration to a human is most preferred. The compounds and compositions of the present invention are useful for the treatment and/or prophylaxis of cardiovascular disease, for raising serum HDL cholesterol levels, for lowering serum triglyceride levels and for lower  
10 serum LDL cholesterol levels. Elevated triglyceride and LDL levels, and low HDL levels, are risk factors for the development of heart disease, stroke, and circulatory system disorders and diseases.

The compounds and compositions of the present invention  
15 are also useful for treating and/or preventing obesity.

Further, these compounds and compositions are useful for the treatment and/or prophylaxis of non-insulin dependent diabetes mellitus (NIDDM) with reduced or no body weight gains by the patients. Furthermore, the compounds and  
20 compositions of the present invention are useful to treat or prevent acute or transient disorders in insulin sensitivity, such as sometimes occur following surgery, trauma, myocardial infarction, and the like. The physician of ordinary skill will know how to identify humans who will  
25 benefit from administration of the compounds and compositions of the present invention.

The present invention further provides a method for the treatment and/or prophylaxis of hyperglycemia in a human or non-human mammal which comprises administering an effective,  
30 non-toxic amount of a compound of the general formula (I), or a tautomeric form thereof and/or a pharmaceutically

acceptable salt thereof to a hyperglycemic human or non-human mammal in need thereof.

They are useful as therapeutic substances in preventing or treating Syndrome X, diabetes mellitus and related  
5 endocrine and cardiovascular disorders and diseases in human or non-human animals.

The invention also relates to the use of a compound of Formula I as described above, for the manufacture of a medicament for treating a PPAR $\alpha$  mediated condition.

10 A therapeutically effective amount of a compound of Structural Formula I can be used for the preparation of a medicament useful for treating Syndrome X, diabetes, treating obesity, lowering tryglyceride levels, lowering serum LDL levels, raising the plasma level of high density lipoprotein, and for treating, preventing or reducing the risk of developing atherosclerosis, and for preventing or reducing the risk of having a first or subsequent  
15 atherosclerotic disease event in mammals, particularly in humans. In general, a therapeutically effective amount of a compound of the present invention typically reduces serum triglyceride levels of a patient by about 20% or more, and increases serum HDL levels in a patient. Preferably, HDL levels will be increased by about 30% or more. In addition, a therapeutically effective amount of a compound, used to  
20 prevent or treat NIDDM, typically reduces serum glucose levels, or more specifically HbA1c, of a patient by about 0.7% or more.

Advantageously, compositions containing the compound of Structural Formula I or the salts thereof may be provided in  
30 dosage unit form, preferably each dosage unit containing from about 1 to about 500 mg be administered although it will, of course, readily be understood that the amount of

the compound or compounds of Structural Formula I actually to be administered will be determined by a physician, in the light of all the relevant circumstances.

When used herein Syndrome X includes pre-diabetic  
5 insulin resistance syndrome and the resulting complications thereof, insulin resistance, non-insulin dependent diabetes, dyslipidemia, hyperglycemia obesity, coagulopathy, hypertension and other complications associated with diabetes. The methods and treatments mentioned herein  
10 include the above and encompass the treatment and/or prophylaxis of any one of or any combination of the following: pre-diabetic insulin resistance syndrome, the resulting complications thereof, insulin resistance, Type II or non-insulin dependent diabetes, dyslipidemia,  
15 hyperglycemia, obesity and the complications associated with diabetes including cardiovascular disease, especially atherosclerosis.

The compositions are formulated and administered in the same general manner as detailed herein. The compounds of the instant invention may be used effectively alone or in  
20 combination with one or more additional active agents depending on the desired target therapy. Combination therapy includes administration of a single pharmaceutical dosage composition which contains a compound of Structural  
25 Formula I and one or more additional active agents, as well as administration of a compound of Structural Formula I and each active agent in its own separate pharmaceutical dosage formulation. For example, a compound of Structural Formula I or thereof and an insulin secretagogue such as biguanides,  
30 thiazolidinediones, sulfonylureas, insulin, or  $\alpha$ -glucosidase inhibitors can be administered to the patient together in a single oral dosage composition such as a tablet or capsule,

60390102:051903

or each agent administered in separate oral dosage formulations. Where separate dosage formulations are used, a compound of Structural Formula I and one or more additional active agents can be administered at essentially the same time, i.e., concurrently, or at separately staggered times, i.e., sequentially; combination therapy is understood to include all these regimens.

An example of combination treatment or prevention of atherosclerosis may be wherein a compound of Structural Formula I or salts thereof is administered in combination with one or more of the following active agents: antihyperlipidemic agents; plasma HDL-raising agents; antihypercholesterolemic agents, fibrates, vitamins, aspirin, and the like. As noted above, the compounds of Structural Formula I can be administered in combination with more than one additional active agent.

Another example of combination therapy can be seen in treating diabetes and related disorders wherein the compounds of Structural Formula I, salts thereof can be effectively used in combination with, for example, sulfonylureas, biguanides, thiazolidinediones,  $\alpha$ -glucosidase inhibitors, other insulin secretagogues, insulin as well as the active agents discussed above for treating atherosclerosis.

The compounds of the present invention, and the pharmaceutically acceptable salt thereof, have valuable pharmacological properties and can be used in pharmaceutical compositions containing a therapeutically effective amount of a compound of the present invention, or pharmaceutically acceptable salts thereof, in combination with one or more pharmaceutically acceptable excipients. Excipients are inert substances such as, without limitation carriers,

diluents, fillers, flavoring agents, sweeteners, lubricants, solubilizers, suspending agents, wetting agents, binders, disintegrating agents, encapsulating material and other conventional adjuvants. Proper formulation is dependent upon the route of administration chosen. Pharmaceutical compositions typically contain from about 1 to about 99 weight percent of the active ingredient which is a compound of the present invention.

Preferably, the pharmaceutical formulation is in unit dosage form. A "unit dosage form" is a physically discrete unit containing a unit dose, suitable for administration in human subjects or other mammals. For example, a unit dosage form can be a capsule or tablet, or a number of capsules or tablets. A "unit dose" is a predetermined quantity of the active compound of the present invention, calculated to produce the desired therapeutic effect, in association with one or more pharmaceutically-acceptable excipients. The quantity of active ingredient in a unit dose may be varied or adjusted from about 0.1 to about 1000 milligrams or more according to the particular treatment involved.

The dosage regimen utilizing the compounds of the present invention is selected by one of ordinary skill in the medical or veterinary arts, in view of a variety of factors, including, without limitation, the species, age, weight, sex, and medical condition of the recipient, the severity of the condition to be treated, the route of administration, the level of metabolic and excretory function of the recipient, the dosage form employed, the particular compound and salt thereof employed, and the like.

Preferably, the compounds of the present invention are administered in a single daily dose, or the total daily dose may be administered in divided doses, two, three, or more

times per day. Where delivery is via transdermal forms, of course, administration is continuous.

Suitable routes of administration of pharmaceutical compositions of the present invention include, for example, oral, eyedrop, rectal, transmucosal, topical, or intestinal administration; parenteral delivery (bolus or infusion), including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections. The compounds of the invention can also be administered in a targeted drug delivery system, such as, for example, in a liposome coated with endothelial cell-specific antibody.

For oral administration, the compounds can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, powders, sachets, granules, dragees, capsules, liquids, elixers, tinctures, gels, emulsions, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained by combining the active compound with a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.

For oral administration in the form of a tablet or capsule, the active ingredient may be combined with an oral, non-toxic, pharmaceutically-acceptable carrier, such as, without limitation, lactose, starch, sucrose, glucose, methyl cellulose, calcium carbonate, calcium phosphate, calcium sulfate, sodium carbonate, mannitol, sorbitol, and

50390102-061908

the like; together with, optionally, disintegrating agents, such as, without limitation, cross-linked polyvinyl pyrrolidone, maize, starch, methyl cellulose, agar, bentonite, xanthan gum, alginic acid, or a salt thereof such as sodium alginate, and the like; and, optionally, binding agents, for example, without limitation, gelatin, acacia, natural sugars, beta-lactose, corn sweeteners, natural and synthetic gums, acacia, tragacanth, sodium alginate, carboxymethyl-cellulose, polyethylene glycol, waxes, and the like; and, optionally, lubricating agents, for example, without limitation, magnesium stearate, sodium stearate, stearic acid, sodium oleate, sodium benzoate, sodium acetate, sodium chloride, talc, and the like. When a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.

Solid form formulations include powders, tablets and capsules. A solid carrier can be one or more substance which may also act as flavoring agents, lubricants, solubilisers, suspending agents, binders, tablet disintegrating agents and encapsulating material.

In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

Various other materials may be present as coatings or to modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and

propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor.

Sterile liquid formulations include suspensions, emulsions, syrups, and elixirs. The active ingredient can be dissolved or suspended in a pharmaceutically acceptable carrier, such as sterile water, sterile organic solvent, or a mixture of both sterile water and sterile organic solvent.

The active ingredient can also be dissolved in a suitable organic solvent, for example, aqueous propylene glycol. Other compositions can be made by dispersing the finely divided active ingredient in aqueous starch or sodium carboxymethyl cellulose solution or in a suitable oil.

Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added.

All formulations for oral administration should be in dosages suitable for such administration. Particularly suitable compositions for oral administration are unit dosage forms such as tablets and capsules.

5 For parental administration the compounds of the present invention, or salts thereof, can be combined with sterile aqueous or organic media to form injectable solutions or suspensions. Formulations for injection may be presented in unit dosage form, such as in ampoules or in  
10 multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. The pharmaceutical forms suitable for  
15 injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that each syringability exists. It must be  
20 stable under the conditions of manufacture and storage and must be preserved against any contamination. The carrier can be solvent or dispersion medium containing, for example, water, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological  
25 saline buffer, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent  
30 the growth of microorganisms.

The injectable solutions prepared in this manner can then be administered intravenously, intraperitoneally,

subcutaneously, or intramuscularly, with intramuscular administration being preferred in humans.

For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation.

5 Such penetrants are generally known in the art. The active compounds can also be administered intranasally as, for example, liquid drops or spray.

For buccal administration, the compositions may take the form of tablets or lozenges formulated in a conventional  
10 manner.

For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of a dry powder inhaler, or an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g.,  
5 dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered  
10 amount. Capsules and cartridges of gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

Pharmaceutical compositions of the present invention  
25 can be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

In making the compositions of the present invention,  
30 the active ingredient will usually be admixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet,

150390172-061900

paper or other container. When the carrier serves as a diluent, it may be a solid, lyophilized solid or paste, semi-solid, or liquid material which acts as a vehicle, or can be in the form of tablets, pills, powders, lozenges, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), or ointment, containing, for example, up to 10% by weight of the active compound. The compounds of the present invention are preferably formulated prior to administration.

The following pharmaceutical formulations 1 and 2 are illustrative only and are not intended to limit the scope of the invention in any way. "Active Ingredient", refers to a compound according to Structural Formula I or salts thereof.

#### Formulation 1

Hard gelatin capsules are prepared using the following ingredients:

	Quantity (mg/capsule)
Active Ingredient	250
Starch, dried	200
Magnesium stearate	<u>10</u>
Total	460 mg

#### Formulation 2

A tablet is prepared using the ingredients below:

	Quantity (mg/tablet)
Active Ingredient	250
Cellulose, microcrystalline	400
Silicon dioxide, fumed	10

Stearic acid

5

Total

665 mg

The components are blended and compressed to form tablets each weighing 665 mg .

5 In yet another embodiment of the compounds of the present invention, the compound is radiolabelled, such as with carbon-14, or tritiated. Said radiolabelled or tritiated compounds are useful as reference standards for in vitro assays to identify new PPAR $\alpha$  and or PPAR $\delta$  agonists.


#### SYNTHESIS

Compounds of the present invention have been formed as specifically described in the examples. Further, many compounds were prepared as more generally as shown in the following schematic. Alternative synthesis methods may also be effective and are known to the skilled artisan.

#### Scheme 1

20 General Experimental Procedure for the synthesis of amide products.

#### PREPARATION 1



25 STEP 1



## 3-Bromo-propan-1-ol

1,3-propanediol (10.26 g, 134.8 mmol) was dissolved in benzene (150 mL). HBr 48% (16.84 mL) was added to the solution and then refluxed under azeotropic removal of water for 24 h. The solvent was distilled at atmospheric pressure. The residue was diluted with ether and (150 mL) and washed with water (3 x 50) mL. The organic layer was dried over  $\text{MgSO}_4$  and concentrated to afford a yellowish oil.  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 200.15 MHz): 3.80 (t, 2H,  $J=6.4$ ), 3.54 (t, 2H,  $J=6.5$ ), 2.10 (qn, 2H,  $J=6.4$ ).

## STEP 2


(2S)-3-[4-(3-Bromo-propoxy)-phenyl]-2-methoxy-propionic acid ethyl ester

A solution of triphenylphosphine (4.77 mmol, 1250 mg) in 50 mL of dry toluene was treated at 0 °C with diisopropylazodicarboxylate (4.77 mmol, 964.5 mg) and stirred for 20 min. A solution of (2S)-3-(4-Hydroxy-phenyl)-2-methoxy-propionic acid ethyl ester (example 1, step 1) (4.46 mmol, 1000 mg) and 3-Bromo-propan-1-ol (example 2, step 1) (4.77 mmol, 663 mg) in 10 mL of dry THF was added to the solution, and the mixture stirred at room temperature overnight. The mixture was concentrated to dryness under vacuum and purified by silica gel chromatography (silica gel, hexanes/ethyl acetate 6:1). The fraction with  $R_f$  0.4 corresponding to the coupled compound was combined and concentrated to dryness to afford a yellow oil. MS (ES) for  $\text{C}_{15}\text{H}_{21}\text{BrO}_4$   $[\text{M}+\text{Na}]^+$ : 367.2.

## PREPARATION 2

## STEP 1


5



3-(4-Benzyloxy-phenyl)-2-ethoxy-3-hydroxy-propionic acid  
ethyl ester

The title compound was prepared from 4-benzyloxybenzaldehyde, lithium diisopropylamide and ethyl 2-ethoxyacetate via the same procedure used for the preparation of 3-(3-benzyloxy-phenyl)-3-hydroxy-2-methoxypropionic acid methyl ester (example 9, step 1). MS (ES) for  $C_{20}H_{24}O_5$   $[M+H_2O-H]^+$ : 327,  $[M+Na]^+$ : 367.4.


## STEP 2



3-(4-Benzyloxy-phenyl)-2-ethoxy-acrylic acid ethyl ester

The title compound was prepared from 3-(4-benzyloxy-phenyl)-2-ethoxy-3-hydroxy-propionic acid ethyl ester (example 93, step 1) via the same procedure used for the preparation of 3-(4-benzyloxy-phenyl)-2-ethoxy-acrylic acid methyl ester. MS (ES) for  $C_{20}H_{22}O_4$   $[M+H]^+$ : 327.2.

## STEP 3




5

## 3-(4-Benzyloxy-phenyl)-2-ethoxy-propionic acid methyl ester

The title compound was prepared from 3-(4-Benzyloxy-phenyl)-2-ethoxy-acrylic acid ethyl ester (example 93, step 2) (3.3 gr, 10.12 mmol) via the same procedure used for the preparation of 3-(3-Benzyloxy-phenyl)-2-methoxy-propionic acid methyl ester (example 9, step 3) to produce an oil that was purified by chromatography (silica gel, hexanes/ethyl acetate 6:1) to produce two compounds: 3-(4-Benzyloxy-phenyl)-propionic acid methyl ester (1.5 gr, Rf aprox. 0.65) and the desired compound (1.5 gr, Rf aprox. 0.2). MS (ES) for  $C_{19}H_{22}O_4$   $[M+NH_4]^+$ : 332.3.

## STEP 4

20




## 2-Ethoxy-3-(4-hydroxy-phenyl)-propionic acid methyl ester

The title compound was prepared from 3-(4-Benzyloxy-phenyl)-2-ethoxy-propionic acid methyl ester (example 93, step 3) via the same procedure used for the preparation of 3-(3-Hydroxy-phenyl)-2-methoxy-propionic acid methyl ester


(example 9, step 4) to produce a yellow oil. MS (ES) for  $C_{12}H_{16}O_4$   $[M+H]^+$ : 225.2,  $[M+NH_4]^+$ : 242.2,  $[M+Na]^+$ : 247.2.

## PREPARATION 3

- 5 (2S)-2-methoxy-3-(4-{2-oxo-2-[4-(4-trifluoromethyl-phenyl)-piperazin-1-yl]-ethoxy}-phenyl)-propionic acid




Step 1: (2S)-3-(4-tert-butoxycarbonylmethoxy-phenyl)-2-methoxy-propionic acid ethyl ester




The compound of (2S)-3-(4-hydroxy-phenyl)-2-methoxy-propionic acid ester (example 1, step 1), (1.2 g, 5.3 mmol) was dissolved in 25 ml of anhydrous THF and NaH (380 mg, 15.8 mmol) was added portion wise. After about 5 minutes, bromo-acetic acid tert-butyl ester was added dropwise at room temperature. The mixture was stirred for 2 hours at room temperature. The crude was dissolved in ethyl acetate (100 ml) and a solution of 5% HCl was added. The mixture was extracted with ethyl acetate (3 X 100 ml), and the combined organic layers were dried over (MgSO<sub>4</sub>) and then concentrated under vacuum. The crude was purified by column chromatography (silica gel, hexane/ethyl acetate 8.5: 1,5) to afford a yellow oil.

- 25 Step 2: (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester



The compound of (2S)-3-(4-tert-butoxycarbonylmethoxyphenyl)-2-methoxypropionic acid ethyl ester (PREPARATION 3, step 1) (1.2 gr, 3.5 mmol) was solved in dichloromethane (5 ml) and trifluoroacetic acid was added (5 ml). The mixture was stirred for an hour, and the crude was concentrated to afford a yellow oil. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 200.15 MHz): 7.16 (d, 2H, J = 8.3), 6.75 (d, 2H, J = 8.3), 4.89 (s, 2H), 4.14 (c, 2H, J = 6.9), 3.94 (t, 1H, J = 6.9), 3.57 (dc, 1H), 3.35 (dc, 1H), 2.92 (d, 2H, J = 6.9), 1.23-1.10 (2t, 6H).


Step 3: (2S)-2-methoxy-3-(4-{2-oxo-2-[4-(4-trifluoromethylphenyl)-piperazin-1-yl]-ethoxy}-phenyl)-propionic acid




The title compound was prepared from (2S)-3-(4-carboxymethoxyphenyl)-2-methoxypropionic acid ethyl ester (PREPARATION 3, step 2) and 1-(4-trifluoromethylphenyl)-piperazine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxyphenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for C<sub>23</sub>H<sub>25</sub>F<sub>3</sub>NO<sub>5</sub> [M+H]<sup>+</sup>: 467.

## PREPARATION 4

3-(3-{[2-(4-ethyl-phenyl)-ethylcarbamoyl]-methoxy}-phenyl)-  
2-methoxy-propionic acid (isomer 1)




Step 1: 3-(3-tert-butoxycarbonylmethoxy-phenyl)-2-methoxy-  
propionic acid methyl ester




The title compound was prepared from 3-(3-hydroxy-phenyl)-2-methoxy-propionic acid methyl ester (example 9, step 4) via the same procedure used to prepare (2S)-3-(4-tert-butoxycarbonylmethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 1) to produce a yellow oil. MS (ES) for  $C_{17}H_{24}O_6$   $[M+H]^+$ : 325.

Step 2: 3-(3-carboxymethoxy-phenyl)-2-methoxy-propionic  
acid methyl ester



The title compound was prepared from 3-(3-tert-butoxycarbonylmethoxy-phenyl)-2-methoxy-propionic acid methyl ester (PREPARATION 4, step 1) via the same procedure used to prepare (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) to produce a yellow oil. MS (ES) for  $C_{13}H_{16}O_6$   $[M+H]^+$ : 269.


Step 3: 3-(3-{[2-(4-ethyl-phenyl)-ethylcarbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid (isomer-1)




The title compound was prepared from 3-(3-carboxymethoxy-phenyl)-2-methoxy-propionic acid methyl ester (PREPARATION 4, step 2) and 2-(4-ethyl-phenyl)-ethylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{22}H_{27}NO_5$   $[M+H]^+$ : 386.

#### PREPARATION 5

(2S)-2-methoxy-3-[4-(1-methyl-1-octylcarbamoyl-ethoxy)-phenyl]-propionic acid



Step 1: (2S)-3-[4-(1-tert-butoxycarbonyl-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid ethyl ester




The title compound was prepared from (2S)-3-(4-hydroxy-phenyl)-2-methoxy-propionic acid ester (example 1, step 1) and 2-bromo-2-methyl-propionic acid tert-butyl ester via the same procedure used to prepare (2S)-3-(4-tert-butoxycarbonylmethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (example 121, step 1) to produce a yellow oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 200.15 MHz): δ 7.10 (d, 2H, J = 8.3), 6.77 (d, 2H, J = 8.3), 4.17 (c, 2H, J = 6.9), 3.90 (t, 1H, J = 6.5), 3.34 (s, 3H), 2.93 (d, 2H, J = 6.5), 1.55 (s, 3H), 1.43 (s, 9H), 1.23-1.4 (t, 3H, J = 6.9).


5

Step 2: (2S)-3-[4-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid ethyl ester



The title compound was prepared from (2S)-3-[4-(1-tert-butoxycarbonyl-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid ethyl ester (PREPARATION 5, step 1) via the same procedure used to prepare (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (example 121, step 2) to produce a yellow oil. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 200.15 MHz): 7.10 (d, 2H, J = 8.3), 6.77 (d, 2H, J = 8.3), 4.14 (c, 2H, J = 6.9), 3.89 (t, 1H, J = 6.5), 3.34 (s, 3H), 2.94 (d, 2H, J = 6.5), 1.55 (s, 6H), 1.19 (t, 3H, J = 6.9).

Step 3: (2S)-2-methoxy-3-[4-(1-methyl-1-octylcarbamoyl-ethoxy)-phenyl]-propionic acid




The title compound was prepared from (2S)-3-[4-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid ethyl ester (PREPARATION 5, step 2) and heptylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-

propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{21}H_{33}NO_5$   $[M+H]^+$ : 380.


5

## EXAMPLE 1

(2S,1'R)-2-Ethoxy-3-(4-{1'-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid




Step 1: (2S,1'R)-3-[4-(1'-benzyloxycarbonyl-ethoxy)-phenyl]-2-ethoxy-propionic acid ethyl ester




The title compound was prepared from (2S)-2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid methyl ester (isomer 2 of Preparation 2, step 4 after chiral separation) (2.9 mmol) and (2S)-2-hydroxy-propionic acid benzyl ester (4.35 mmol) via the same procedure used for the preparation of (2S)-3-[4-(3-bromo-propoxy)-phenyl]-2-methoxy-propionic acid ethyl ester (Preparation 1, step 2) and purified by chromatography (silica gel, hexanes/ethyl acetate 6:1,  $R_f$  0.27) to produce a colorless oil. MS (ES) for  $C_{23}H_{28}O_6$   $[M+NH_4]^+$ : 418.2,  $[M+Na]^+$ : 423.2.

Step 2: (2S,1'R)-3-[4-(1'-carboxy-ethoxy)-phenyl]-2-ethoxy-propionic acid



The title compound was prepared from (2S,1R)-3-[4-(1-benzyloxycarbonyl-ethoxy)-phenyl]-2-ethoxy-propionic acid ethyl ester (Example 1, step 1) via the same procedure used for the preparation of 3-(3-hydroxy-phenyl)-2-methoxy-propionic acid methyl ester (example 9, step 4) to produce a yellow oil. MS (ES) for  $C_{16}H_{22}O_6$   $[M+NH_4]^+$ : 328.2.


Step 3: (2S,1'R)-2-ethoxy-3-(4-{1'-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid



(2S,1'R)-3-[4-(1'-carboxy-ethoxy)-phenyl]-2-ethoxy-propionic acid (Example 1, step 2) (0.1 mmol) was dissolved in dichloromethane in a 16x100 mm tube, triethylamine (0.15 mmol), eimethylaminopyridine (0.01 mmol), PyBroP (0.2 mmol) and 2-(4-phenoxy-phenyl)-ethylamine (0.15 mmol) were added and the mixture was stirred overnight at room temperature. The mixture was concentrated to dryness under vacuum. The crude was dissolved in MeOH and charged into a 500 mg SCX column (previously pre-conditioned with MeOH). The column was washed (2 x 2 ml) with MeOH. The crude was concentrated, and the residue reconstituted in a mixture of Ethanol (2 ml) and NaOH (1M in water, 1 mL), which was stirred at room temperature until the hydrolysis was completed by HPLC-MS. Then HCl (1M in water) was added (until pH=3) and the solvent was eliminated under vacuum. The residue was reconstituted in  $CH_2Cl_2/H_2O$  and filtered through a hydrophobic syringe. The organic layer was separated, concentrated and purified by HPLC-MS to produce the compound as a colorless oil. MS (ES) for  $C_{28}H_{31}NO_6$   $[M+H]^+$ : 478.2.

## EXAMPLE 2


(2S,1'R)-2-Ethoxy-3-(4-{1'-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid



- 5 The title compound was prepared from 2-(4-ethyl-phenyl)-ethylamine and (2S,1'R)-3-[4-(1'-carboxy-ethoxy)-phenyl]-2-ethoxy-propionic acid (Example 1, step 2) via the same procedure used for the preparation of (2S,1'R)-2-ethoxy-3-(4-{1'-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{24}H_{31}NO_5$   $[M+H]^+$ : 414.2.

## EXAMPLE 3

(2S,1'R)-2-ethoxy-3-(4-{1'-[2-(4-trifluoromethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid




- 15 The title compound was prepared from 2-(4-trifluoromethyl-phenyl)-ethylamine and (2S,1'R)-3-[4-(1'-Carboxy-ethoxy)-phenyl]-2-ethoxy-propionic acid (Example 1, step 2) via the same procedure used for the preparation of (2S,1'R)-2-ethoxy-3-(4-{1'-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{23}H_{26}F_3NO_5$   $[M+H]^+$ : 454.2,  $[M-H]^-$ : 452.2.

20

## EXAMPLE 4

(2S,1'R)-3-{4-[1'-(4-tert-butyl-cyclohexylcarbamoyl)-ethoxy]-phenyl}-2-ethoxy-propionic acid




The title compound was prepared from a mixture of cis/trans (2:3) of 4-tert-butyl-cyclohexylamine and (2S,1'R)-3-[4-(1'-carboxy-ethoxy)-phenyl]-2-ethoxy-propionic acid (Example 1, step 2) via the same procedure used for the preparation of (2S,1'R)-2-ethoxy-3-(4-{1'-[2-(4-phenoxy-phenyl)-ethyl]carbamoyl}-ethoxy)-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil.

MS (ES) for  $C_{24}H_{37}NO_5$   $[M+H]^+$ :420.3,  $[M+NH_4]^+$ :442.3,  $[M+H]^+$ :418.2.

#### EXAMPLE 5


(2S,1'R)-2-ethoxy-3-(4-{1'-[2-(2-ethoxy-phenyl)-ethyl]carbamoyl}-ethoxy)-phenyl)-propionic acid



The title compound was prepared from 2-(2-ethoxy-phenyl)-ethylamine and (2S,1'R)-3-[4-(1'-carboxy-ethoxy)-phenyl]-2-ethoxy-propionic acid (Example 1, step 2) via the same procedure used for the preparation of (2S,1'R)-2-ethoxy-3-(4-{1'-[2-(4-phenoxy-phenyl)-ethyl]carbamoyl}-ethoxy)-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{24}H_{31}NO_6$   $[M+H]^+$ : 430.2.

#### EXAMPLE 6


(2S,1'R)-2-ethoxy-3-{4-[1'-(3-trifluoromethyl-benzyl)carbamoyl]-ethoxy}-phenyl)-propionic acid



The title compound was prepared from 3-trifluoromethyl-benzylamine and (2S,1'R)-3-[4-(1'-carboxy-ethoxy)-phenyl]-2-ethoxy-propionic acid (Example 1, step 2) via the same procedure used for the preparation of (2S,1'R)-2-ethoxy-3-(4-{1'-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{22}H_{24}F_3NO_5$   $[M+H]^+$ : 440.2.

#### EXAMPLE 7


(2S,1'R)-2-ethoxy-3-[4-[1'-(3-fluoro-5-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl]-propionic acid



The title compound was prepared from 3-fluoro-5-trifluoromethyl-benzylamine and (2S,1'R)-3-[4-(1'-Carboxy-ethoxy)-phenyl]-2-ethoxy-propionic acid (Example 1, step 2) via the same procedure used for the preparation of (2S,1'R)-2-ethoxy-3-(4-{1'-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{22}H_{23}F_4NO_5$   $[M-H]^-$ : 456.1.

#### EXAMPLE 8


(2S,1'R)-3-(4-{1'-[(biphenyl-3-ylmethyl)-carbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid



The title compound was prepared from C-biphenyl-3-yl-methylamine and (2S,1'R)-3-[4-(1'-carboxy-ethoxy)-phenyl]-2-ethoxy-propionic acid (Example 1, step 2) via the same procedure used for the preparation of (2S,1'R)-2-Ethoxy-3-(4-{1'-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{27}H_{29}NO_5$   $[M+H]^+$ : 448.2.

## EXAMPLE 9


(2S,1'R)-3-(4-{1'-[2-(3-chloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid



The title compound was prepared from 2-(3-chloro-phenyl)-ethylamine and (2S,1'R)-3-[4-(1'-carboxy-ethoxy)-phenyl]-2-ethoxy-propionic acid (Example 1, step 2) via the same procedure used for the preparation of (2S,1'R)-2-ethoxy-3-(4-{1'-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{22}H_{26}ClNO_5$   $[M+H]^+$ : 420.2.

## EXAMPLE 10


(2S,1'R)-2-ethoxy-3-(4-{1'-[2-(3-fluoro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid.



The title compound was prepared from [2-(3-fluoro-phenyl)-ethyl]-methyl-amine and (2S,1'R)-3-[4-(1'-carboxy-ethoxy)-phenyl]-2-ethoxy-propionic acid (Example 1, step 2) via the same procedure used for the preparation of (2S,1'R)-2-ethoxy-3-(4-{1'-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{22}H_{26}FNO_5$   $[M+H]^+$ : 404.2.

## EXAMPLE 11


(2S,1'R)-2-ethoxy-3-(4-{1'-[2-(2-fluoro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid



The title compound was prepared from [2-(2-fluoro-phenyl)-ethyl]-methyl-amine and (2S,1'R)-3-[4-(1'-carboxy-ethoxy)-phenyl]-2-ethoxy-propionic acid (Example 1, step 2) via the same procedure used for the preparation of (2S,1'R)-2-ethoxy-3-(4-{1'-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{22}H_{26}FNO_5$   $[M+H]^+$ : 404.2.

## EXAMPLE 12


(2S,1'R)-3-(4-{1'-[2-(2,4-dichloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid



The title compound was prepared from 2-(2,4-dichloro-phenyl)-ethylamine and (2S,1'R)-3-[4-(1'-carboxy-ethoxy)-phenyl]-2-ethoxy-propionic acid (Example 1, step 2) via the same procedure used for the preparation of (2S,1'R)-2-ethoxy-3-(4-{1'-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{22}H_{25}Cl_2NO_5$   $[M+H]^+$ : 454.1.

## EXAMPLE 13


(2S,1'R)-3-(4-{1'-[2-(2,6-dichloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid



The title compound was prepared from 2-(2,6-dichloro-phenyl)-ethylamine and (2S,1'R)-3-[4-(1'-carboxy-ethoxy)-phenyl]-2-ethoxy-propionic acid (Example 1, step 2) via the same procedure used for the preparation of (2S,1'R)-2-ethoxy-3-(4-{1'-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{22}H_{25}Cl_2NO_5$   $[M+H]^+$ : 454.1.

## EXAMPLE 14

(2S,1'R)-2-ethoxy-3-[4-(1'-heptylcarbamoyl-ethoxy)-phenyl]-propionic acid




The title compound was prepared from heptylamine and (2S,1'R)-3-[4-(1'-Carboxy-ethoxy)-phenyl]-2-ethoxy-propionic acid (Example 1, step 2) via the same procedure used for the preparation of (2S,1'R)-2-ethoxy-3-(4-{1'-[2-(4-phenoxy-phenyl)-

ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{21}H_{33}NO_5$   $[M+H]^+$ : 380.3.

## EXAMPLE 15


- 5 (2S,1'R)-3-(4-{1'-[2-(2-chloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid



The title compound was prepared from 2-(2-chloro-phenyl)-ethylamine and (2S,1'R)-3-[4-(1'-carboxy-ethoxy)-phenyl]-2-ethoxy-propionic acid (Example 1, step 2) via the same procedure used for the preparation of (2S,1'R)-2-ethoxy-3-(4-{1'-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{22}H_{26}ClNO_5$   $[M+H]^+$ : 420.2.

## EXAMPLE 16


- 15 (2S,1'R)-3-(4-{1'-[2-(4-tert-butyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid



The title compound was prepared from 2-(4-tert-butyl-phenyl)-ethylamine and (2S,1'R)-3-[4-(1'-carboxy-ethoxy)-phenyl]-2-ethoxy-propionic acid (Example 1, step 2) via the same procedure used for the preparation of (2S,1'R)-2-ethoxy-3-(4-{1'-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{26}H_{35}NO$   $[M+H]^+$ : 442.5.

## EXAMPLE 17


(2S,1'R)-2-ethoxy-3-{4-[1'-(4-fluoro-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid



- 5 The title compound was prepared from 4-fluoro-benzylamine and (2S,1'R)-3-[4-(1'-carboxy-ethoxy)-phenyl]-2-ethoxy-propionic acid (Example 1, step 2) via the same procedure used for the preparation of (2S,1'R)-2-ethoxy-3-(4-{1'-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{21}H_{24}FNO_5$   $[M+H]^+$ : 390.4.

## EXAMPLE 18

(2S,1'R)-2-ethoxy-3-{4-[1'-(4-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid




- 15 The title compound was prepared from 4-trifluoromethyl-benzylamine and (2S,1'R)-3-[4-(1'-Carboxy-ethoxy)-phenyl]-2-ethoxy-propionic acid (Example 1, step 2) via the same procedure used for the preparation of (2S,1'R)-2-ethoxy-3-(4-{1'-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{22}H_{24}F_3NO_5$   $[M+H]^+$ : 440.3.

## EXAMPLE 19

(2S,1'R)-2-ethoxy-3-{4-[1'-(2-thiophen-2-yl-ethylcarbamoyl)-ethoxy]-phenyl}-propionic acid

chiral




- 5 The title compound was prepared from 2-thiophen-2-yl-ethylamine and (2S,1'R)-3-[4-(1'-carboxy-ethoxy)-phenyl]-2-ethoxy-propionic acid (Example 1, step 2) via the same procedure used for the preparation of (2S,1'R)-2-ethoxy-3-(4-{1'-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a yellow oil. MS (ES) for  $C_{20}H_{25}NO_5S$   $[M+H]^+$ : 392.3.

## EXAMPLE 20

(2S,1'R)-2-ethoxy-3-(4-{1'-[(thiophen-2-ylmethyl)-carbamoyl]-ethoxy}-phenyl)-propionic acid

chiral




- 15 The title compound was prepared from C-thiophen-2-yl-methylamine and (2S,1'R)-3-[4-(1'-carboxy-ethoxy)-phenyl]-2-ethoxy-propionic acid (Example 1, step 2) via the same procedure used for the preparation of (2S,1'R)-2-ethoxy-3-(4-{1'-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a yellow oil. MS (ES) for  $C_{19}H_{23}NO_5S$   $[M+H]^+$ : 378.3.

## EXAMPLE 21

(2S,1'R)-3-{4-[1'-(4-tert-butyl-benzylcarbamoyl)-ethoxy]-phenyl}-2-ethoxy-propionic acid


acid



The title compound was prepared from 4-tert-butyl-benzylamine and (2S,1'R)-3-[4-(1'-carboxy-ethoxy)-phenyl]-2-ethoxy-propionic acid (Example 1, step 2) via the same procedure used for the preparation of (2S,1'R)-2-ethoxy-3-(4-{1'-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{25}H_{33}NO_5$   $[M+H]^+$ : 428.4.

## EXAMPLE 22


(2S,1'R)-3-{4-[1'-(4-tert-butyl-phenylcarbamoyl)-ethoxy]-phenyl}-2-ethoxy-propionic acid



The title compound was prepared from 4-tert-butyl-phenylamine and (2S,1'R)-3-[4-(1'-carboxy-ethoxy)-phenyl]-2-ethoxy-propionic acid (Example 1, step 2) via the same procedure used for the preparation of (2S,1'R)-2-ethoxy-3-(4-{1'-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{24}H_{31}NO_5$   $[M+H]^+$ : 414.4.

## EXAMPLE 23


(2S,1'R)-3-{4-[1'-(4-trans-tert-butyl-cyclohexylcarbamoyl)-ethoxy]-phenyl}-2-ethoxy-propionic acid



The title compound was prepared from trans 4-tert-butyl-cyclohexylamine and (2S,1'R)-3-[4-(1'-carboxy-ethoxy)-phenyl]-2-ethoxy-propionic acid (Example 1, step 2) via the same procedure used for the preparation of (2S,1'R)-2-ethoxy-3-(4-{1'-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce  
 5 a colorless oil. MS (ES) for  $C_{24}H_{37}NO_5$   $[M+H]^+$ :420.3,  $[M+NH_4]^+$ :442.3.

## EXAMPLE 24


(2S)-3-[4-({ethyl-[2-(4-methoxy-phenyl)-1-methyl-ethyl]-carbamoyl}-methoxy)-phenyl]-2-methoxy-propionic acid  
 10



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and ethyl-[2-(4-methoxy-phenyl)-1-methyl-ethyl]-amine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{24}H_{31}NO_6$   $[M+H]^+$ : 430.  
 15

## EXAMPLE 25

(2S)-2-methoxy-3-{4-[(1-naphthalen-1-yl-ethylcarbamoyl)-methoxy]-phenyl}-propionic acid  
 20




The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 1-naphthalen-1-yl-ethylamine via  
 25

the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{24}H_{25}NO_5$   $[M+H]^+$ : 408.

5

## EXAMPLE 26

(2S)-2-methoxy-3-{4-[(1-phenyl-ethylcarbamoyl)-methoxy]-phenyl}-propionic acid




10 The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 1-phenyl-ethylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{20}H_{23}NO_5$   $[M+H]^+$ : 358.

15

## EXAMPLE 27

(2S)-2-methoxy-3-(4-{[methyl-(1-phenyl-ethyl)-carbamoyl]-methoxy}-phenyl)-propionic acid

20




25

The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and methyl-(1-phenyl-ethyl)-amine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-

ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{21}H_{25}NO_5$   $[M+H]^+$ : 372.

## EXAMPLE 28


5 (2S)-3-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-2-oxo-ethoxy}-phenyl)-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and (4-fluoro-phenyl)-piperidin-4-yl-methanone via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{24}H_{26}FNO_6$   $[M+H]^+$ : 444.

## EXAMPLE 29

(2S)-3-(4-{2-[4-(4-chloro-benzoyl)-piperidin-1-yl]-2-oxo-ethoxy}-phenyl)-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and (4-chloro-phenyl)-piperidin-4-yl-methanone via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1,


step 3) to produce a yellow oil. MS (ES) for  $C_{24}H_{26}ClNO_6$   
 $[M+H]^+$ : 460.

5

## EXAMPLE 30

(2S)-2-methoxy-3-{4-[(1-methoxycarbonyl-2-phenyl-ethylcarbamoyl)-methoxy]-phenyl}-propionic acid


Chiral



The title compound was prepared from (2S)-3-(4-  
 10 carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester  
 (PREPARATION 3, step 2) and 2-amino-3-phenyl-propionic acid  
 methyl ester via the same procedure used for the preparation  
 of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-  
 ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1,  
 15 step 3) to produce a colorless oil. MS (ES) for  $C_{22}H_{25}NO_7$   
 $[M+H]^+$ : 416.

## EXAMPLE 31

(2S)-3-[4-(2-{4-[(4-chloro-phenyl)-phenyl-methyl]-piperazin-  
 20 1-yl}-2-oxo-ethoxy)-phenyl]-2-methoxy-propionic acid




The title compound was prepared from (2S)-3-(4-  
 carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester

(PREPARATION 3, step 2) and 1-[(4-chloro-phenyl)-phenyl-methyl]-piperazine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid

5 (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{29}H_{31}ClN_2O_5$   $[M+H]^+$ : 524.

## EXAMPLE 32

10 (2S)-3-[4-({[(4-chloro-phenyl)-phenyl-methyl]-carbamoyl}-methoxy)-phenyl]-2-methoxy-propionic acid




The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and C-(4-chloro-phenyl)-C-phenyl-methylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a yellow oil. MS (ES) for  $C_{25}H_{24}ClNO_5$

15

20  $[M+H]^+$ : 454.

## EXAMPLE 32


(2S)-3-(4-{[butyl-(1-phenyl-ethyl)-carbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and butyl-(1-phenyl-ethyl)-amine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{24}H_{31}NO_5$   $[M+H]^+$  414.

## EXAMPLE 33


(2S)-3-{4-[(3,3-diphenyl-propylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 3,3-eiphenyl-propylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a yellow oil. MS (ES) for  $C_{27}H_{29}NO_5$   $[M+H]^+$ : 448.

## EXAMPLE 34


(2S)-3-(4-{[benzyl-(2-ethoxycarbonyl-ethyl)-carbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 3-benzylamino-propionic acid ethyl ester via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{24}H_{29}NO_7$   $[M+H]^+$ : 444.

## EXAMPLE 35


(2S)-2-methoxy-3-(4-{[3-(methyl-phenyl-amino)-propylcarbamoyl]-methoxy}-phenyl)-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and N1-methyl-N1-phenyl-propane-1,3-diamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{22}H_{28}N_2O_5$   $[M+H]^+$ : 401.

## EXAMPLE 36


(2S)-2-methoxy-3-(4-{[2-(4-methoxy-phenoxy)-ethylcarbamoyl]-methoxy}-phenyl)-propionic acid



- 5 The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 2-(4-methoxy-phenoxy)-ethylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to  
10 produce a colorless oil. MS (ES) for  $C_{21}H_{25}NO_7$   $[M+H]^+$ : 404.

## EXAMPLE 37

(2S)-2-methoxy-3-{4-[(4-phenoxy-phenylcarbamoyl)-methoxy]-phenyl}-propionic acid



- The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 4-phenoxy-phenylamine via the  
20 same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-


206790-20100209  
60340102-061902

ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{24}H_{23}NO_6$   $[M+H]^+$ : 421.

5

## EXAMPLE 38


2-methoxy-3-{3-[(4-phenoxy-phenylcarbamoyl)-methoxy]-phenyl}-propionic acid (isomer 1)



The title compound was prepared from 3-(3-carboxymethoxy-phenyl)-2-methoxy-propionic acid methyl ester (PREPARATION 4, step 2) and 4-phenoxy-phenylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{24}H_{23}NO_6$   $[M+H]^+$ : 322.

## EXAMPLE 39

(2S)-3-{4-[1-(4-tert-butyl-cyclohexylcarbamoyl)-1-methyl-ethoxy]-phenyl}-2-methoxy-propionic acid




The title compound was prepared from (2S)-3-[4-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid ethyl

ester (PREPARATION 5, step 2) and 4-cis/trans-tert-butyl-cyclohexylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid

5 (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{24}H_{37}NO_5$   $[M+H]^+$ : 420.

## EXAMPLE 40

10 (2S)-2-methoxy-3-(4-{1-methyl-1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid




15 The title compound was prepared from (2S)-3-[4-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid ethyl ester (PREPARATION 5, step 2) and 4-phenoxy-phenylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{28}H_{31}NO_6$   $[M+H]^+$ : 478.

20

## EXAMPLE 41


(2S)-3-(4-{1-[2-(2-ethoxy-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-[4-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid ethyl ester (PREPARATION 5, step 2) and 2-(2-ethoxy-phenyl)-ethylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethyl]carbonyl}-ethoxy)-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{24}H_{31}NO_6$   $[M+H]^+$ : 430.

## EXAMPLE 42


2-methoxy-2-methyl-3-(4-{[2-(4-phenoxy-phenyl)-ethyl]carbonyl}-methoxy)-phenyl)-propionic acid



The title compound was prepared from 3-(4-carboxymethoxy-phenyl)-2-methoxy-2-methyl-propionic acid methyl ester 2-(4-phenoxy-phenyl)-ethylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethyl]carbonyl}-ethoxy)-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{27}H_{29}NO_6$   $[M+H]^+$ : 464.

## EXAMPLE 43


2-methoxy-3-(4-{1-methyl-1-[2-(3-trifluoromethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid



- 5 The title compound was prepared from (2S)-3-[4-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid ethyl ester (PREPARATION 5, step 2) and 2-(3-trifluoromethyl-phenyl)-ethylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{23}H_{26}F_3NO_5$   $[M-H]^-$ : 452.

## EXAMPLE 44


(2S)-2-methoxy-3-{4-[1-methyl-1-(3-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid



- 15 The title compound was prepared from (2S)-3-[4-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid ethyl ester (PREPARATION 5, step 2) and 3-trifluoromethyl-benzylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{22}H_{24}F_3NO_5$   $[M-H]^-$ : 438.

## EXAMPLE 45


(2S)-3-(4-{1-[2-(2-chloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid



- 5 The title compound was prepared from (2S)-3-[4-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid ethyl ester (PREPARATION 5, step 2) and 2-(2-chloro-phenyl)-ethylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{22}H_{26}ClNO_5$  [M-H]<sup>-</sup>: 420.

## EXAMPLE 46


(2S)-3-(4-{1-[(biphenyl-3-ylmethyl)-carbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid



- 15 The title compound was prepared from (2S)-3-[4-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid ethyl ester (PREPARATION 5, step 2) and C-biphenyl-3-yl-methylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{27}H_{29}NO_5$  [M-H]<sup>-</sup>: 446.

## EXAMPLE 47


(2S)-3-(4-{1-[2-(2,5-dimethoxy-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid



5 The title compound was prepared from (2S)-3-[4-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid ethyl ester (PREPARATION 5, step 2) and 2-(2,5-dimethoxy-phenyl)-ethylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{24}H_{31}NO_7$  [M-H]<sup>-</sup>: 445.

## EXAMPLE 48


15 (2S)-3-(4-{1-[2-(2-fluoro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid




The title compound was prepared from (2S)-3-[4-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid ethyl ester (PREPARATION 5, step 2) and 2-(2-fluoro-phenyl)-ethylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{22}H_{26}FNO_5$  [M-H]<sup>-</sup>: 402.

## EXAMPLE 49

(2S)-2-ethoxy-3-(4-{1-methyl-1-[2-(3-trifluoromethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid




Step 1: (2S)-3-[4-(1-tert-butoxycarbonyl-1-methyl-ethoxy)-phenyl]-2-ethoxy-propionic acid ethyl ester



The title compound was prepared (2S)-2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (example 251, step 3) and 2-bromo-2-methyl-propionic acid tert-butyl ester via the same procedure used to prepare (2S)-3-(4-tert-butoxycarbonylmethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 1) to produce a yellow oil.

MS (ES) for  $C_{21}H_{32}O_6$   $[M+H]^+$ : 381.

Step 2: (2S)-3-[4-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-ethoxy-propionic acid ethyl ester




The title compound was prepared from (2S)-3-[4-(1-tert-butoxycarbonyl-1-methyl-ethoxy)-phenyl]-2-ethoxy-propionic acid ethyl ester (EXAMPLE 49, step 1) via the same procedure used to prepare (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-

propionic acid ethyl ester (PREPARATION 3, step 2) to produce a yellow oil.

MS (ES) for  $C_{17}H_{24}O_6$   $[M+H]^+$ : 325.


- 5 Step 3: (2S)-2-ethoxy-3-(4-{1-methyl-1-[2-(3-trifluoromethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid



10 The title compound was prepared from (2S)-3-[4-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-ethoxy-propionic acid ethyl ester (EXAMPLE 49, step 2) and 2-(4-trifluoromethyl-phenyl)-ethylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, 15 step 3) to produce a colorless oil. MS (ES) for  $C_{24}H_{28}F_3NO_5$   $[M-H]^-$ : 466.

#### EXAMPLE 50

- 20 (2S)-2-ethoxy-3-{4-[1-(3-fluoro-5-trifluoromethyl-benzylcarbamoyl)-1-methyl-ethoxy]-phenyl}-propionic acid




- 25 The title compound was prepared from (2S)-3-[4-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-ethoxy-propionic acid ethyl ester (EXAMPLE 49, step 2) and 3-fluoro-5-trifluoromethyl-benzylamine via the same procedure used for the preparation

of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{23}H_{25}F_4NO_5$   $[M-H]^-$ : 470.

5

## EXAMPLE 51


(2S)-3-(4-{1-[2-(2-chloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid



10 The title compound was prepared from (2S)-3-[4-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-ethoxy-propionic acid ethyl ester (EXAMPLE 49, step 2) and 2-(2-chloro-phenyl)-ethylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{23}H_{28}Cl_4NO_5$   $[M-H]^-$ : 434.

## EXAMPLE 52

20 (2S)-3-(4-{1-[(biphenyl-3-ylmethyl)-carbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid



The title compound was prepared from (2S)-3-[4-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-ethoxy-propionic acid ethyl ester (EXAMPLE 49, step 2) and C-biphenyl-3-yl-methylamine via the same procedure used for the preparation of (2S, 1R)-2-


60360102 DE 1902

ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{28}H_{31}NO_5$   $[M-H]^-$ : 462.

5

## EXAMPLE 53


(2S)-3-(4-{1-[2-(3-chloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid



The title compound was prepared from (2S)-3-[4-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-ethoxy-propionic acid ethyl ester (EXAMPLE 49, step 2) and 2-(3-chloro-phenyl)-ethylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{23}H_{28}ClNO_5$   $[M-H]^-$ : 434.

## EXAMPLE 54

(2S)-3-(4-{1-[2-(2,5-dimethoxy-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid



The title compound was prepared from (2S)-3-[4-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-ethoxy-propionic acid ethyl ester (EXAMPLE 49, step 2) and 2-(2,5-dimethoxy-phenyl)-ethylamine via the same procedure used for the preparation of (2S, 1R)-

20050902-20100602


20

2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{25}H_{33}NO_7$   $[M-H]^-$ : 458.

5

## EXAMPLE 55

(2S)-2-ethoxy-3-(4-{1-[2-(2-fluoro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-propionic acid




The title compound was prepared from (2S)-3-[4-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-ethoxy-propionic acid ethyl ester (EXAMPLE 49, step 2) and 2-(2-fluoro-phenyl)-ethylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{23}H_{28}FNO_5$   $[M-H]^-$ : 416.

10

15

## EXAMPLE 56


(2S)-3-{3-[1-(4-tert-butyl-cyclohexylcarbamoyl)-1-methyl-ethoxy]-phenyl}-2-methoxy-propionic acid



20

Step 1: (2S)-3-[3-(1-tert-butoxycarbonyl-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid methyl ester


20061902-20100009



The title compound was prepared from 3-(3-hydroxy-phenyl)-2-methoxy-propionic acid methyl ester ( example 9, step 4) and 2-bromo-2-methyl-propionic acid tert-butyl ester via the same procedure used for the preparation of (2S)-3-(4-tert-butoxy carbonyl- methoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 1) to produce a yellow oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 200.15 MHz) : δ 7.13-7.09 (m, 1H), 6.84-6.69 (m, 3H), 3.95-3.89 (dd, 1H, J = 6.5, 4.4), 3.7 (s, 3H), 3.34 (s, 3H), 2.94-2.90 (m, 2 H), 1.50 (s, 6H), 1.43 (s, 9H).


Step 2: (2S)-3-[3-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid methyl ester



The title compound was prepared from 3-[3-(1-tert-butoxycarbonyl-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid methyl ester (EXAMPLE 56, step 1) via the same procedure used to produce (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) to produce a yellow oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 200.15 MHz) : δ 7.19-7.15 (m, 1H), 6.96-6.79 (m, 3H), 3.96-3.89 (dd, 1H, J = 6.5, 4.4), 3.70 (s, 3H), 3.33 (s, 3H), 2.98-2.94 (m, 2 H), 1.55 (s, 6H).


Step 3: (2S)-3-{3-[1-(4-tert-butyl-cyclohexylcarbamoyl)-1-methyl-ethoxy]-phenyl}-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-[3-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid methyl ester (EXAMPLE 56, step 2) and 4-tert-cis/trans-Butyl-cyclohexylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{24}H_{37}NO_5$   $[M-H]^-$ : 418.

## EXAMPLE 57

(2S)-3-(3-{1-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid




The title compound was prepared from (2S)-3-[3-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid methyl ester (EXAMPLE 56, step 2) and 2-(4-ethyl-phenyl)-ethylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{24}H_{31}NO_5$   $[M-H]^-$ : 412.

## EXAMPLE 58

(2S)-2-methoxy-3-(3-{1-methyl-1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid

5




The title compound was prepared from (2S)-3-[3-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid methyl ester (EXAMPLE 56, step 2) and 4-phenoxy-phenyl amine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{28}H_{31}NO_6$   $[M-H]^-$ : 476.

10

15

## EXAMPLE 59

(2S)-3-{3-[1-(3-fluoro-5-trifluoromethyl-benzylcarbamoyl)-1-methyl-ethoxy]-phenyl}-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-[3-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid methyl ester (EXAMPLE 56, step 2) and 3-fluoro-5-trifluoromethyl-benzylamine amine via the same procedure used for the


20

preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{22}H_{23}F_4NO_5$   $[M-H]^-$ : 456.

5

## EXAMPLE 60


(2S)-3-(3-{1-[(biphenyl-3-ylmethyl)-carbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-[3-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid methyl ester (EXAMPLE 56, step 2) and C-biphenyl-3-yl-methylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{27}H_{28}NO_5$   $[M-H]^-$ : 446.

## EXAMPLE 61

(2S)-3-(3-{1-[2-(3-chloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid




The title compound was prepared from (2S)-3-[3-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid methyl ester (EXAMPLE 56, step 2) and 2-(3-chloro-phenyl)-ethylamine via the same procedure used for the preparation

of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{22}H_{29}ClNO_5$   $[M-H]^-$ : 418.

5

## EXAMPLE 62


(2S)-2-methoxy-3-{4-[(1-phenyl-ethylcarbamoyl)-methoxy]-phenyl}-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 1-phenyl-ethylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a yellow oil. MS (ES) For  $C_{20}H_{23}NO_5$   $[M+H]^+$ : 358.

## EXAMPLE 63

(2S)-3-(3-{1-[2-(2,4-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-[3-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid methyl ester (EXAMPLE 56, step 2) and 2-(2,4-dichloro-phenyl)-ethylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-

25

00390102-061902


ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil.

MS (ES) for  $C_{22}H_{25}ClNO_5$  [M]<sup>+</sup>: 454, [M+2]<sup>+</sup>: 456.

5

## EXAMPLE 64


(2S)-3-(3-{1-[2-(2,6-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-[3-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid methyl ester (EXAMPLE 56, step 2) and 2-(2,6-dichloro-phenyl)-ethylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{22}H_{25}ClNO_5$  [M]<sup>+</sup>: 454, [M+2]<sup>+</sup>: 456.

## EXAMPLE 65

(2S)-3-[3-(1-heptylcarbamoyl-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid




The title compound was prepared from (2S)-3-[3-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid methyl ester (EXAMPLE 56, step 2) and heptylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-

(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{21}H_{33}NO_5$   $[M+H]^+$ : 480.

5

## EXAMPLE 66


(2S)-3-(4-{1-[2-(2,4-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-[4-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid ethyl ester (PREPARATION 5, step 2) and 2-(2,4-dichloro-phenyl)-ethylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{22}H_{25}Cl_2NO_5$   $[M-H]^-$ : 452,  $[M+H]^+$ : 454.

## EXAMPLE 67

(2S)-3-(4-{1-[2-(2,4-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid



The title compound was prepared from (2S)-3-[4-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid ethyl ester (PREPARATION 5, step 2) and 2-(2,4-dichloro-phenyl)-ethylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-


50390102-051902

ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{22}H_{25}Cl_2NO_5$   $[M-H]^-$ : 452,  $[M+H]^+$ : 454.

5

## EXAMPLE 68


(2S)-3-(4-{1-[2-(2,6-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid



The title compound was prepared from (2S)-3-[4-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-ethoxy-propionic acid ethyl ester (EXAMPLE 49, step 2) and 2-(2,6-dichloro-phenyl)-ethylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{23}H_{27}Cl_2NO_5$   $[M-H]^-$ : 466,  $[M+H]^+$ : 468.

## EXAMPLE 69

(2S)-2-ethoxy-3-(4-{1-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-propionic acid




The title compound was prepared from (2S)-3-[4-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-ethoxy-propionic acid ethyl ester (EXAMPLE 49, step 2) and 2-(4-ethyl-phenyl) ethylamine via the same procedure used for the preparation of (2S, 1R)-2-

ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{25}H_{33}NO_5$   $[M+H]^+$  : 428.

5

## EXAMPLE 70


(2S)-2-ethoxy-3-(4-{1-[2-(2-ethoxy-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-propionic acid



The title compound was prepared from (2S)-3-[4-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-ethoxy-propionic acid ethyl ester (EXAMPLE 49, step 2) and 2-(2-ethoxy-phenyl)-ethylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{25}H_{33}NO_6$   $[M+H]^+$ : 444.

## EXAMPLE 71

(2S)-2-ethoxy-3-[4-(1-heptylcarbamoyl-1-methyl-ethoxy)-phenyl]-propionic acid




The title compound was prepared from (2S)-3-[4-(1-carboxy-1-methyl-ethoxy)-phenyl]-2-ethoxy-propionic acid ethyl ester (EXAMPLE 49, step 2) and heptylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-

phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{22}H_{33}NO_5$   $[M+H]^+$ : 394.

## EXAMPLE 72

(R,S)-3-[4-(1-Benzylloxycarbonyl-ethoxy)-phenyl]-2-ethoxy-propionic acid ethyl ester


To a solution of 2-(S)-hydroxypropionic acid benzyl ester (0.966 g, 5.36 mmol) and (S)-2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (1.16 g, 4.88 mmol) in THF (30 ml) was added the triphenyl phosphine (1.66 g, 6.34 mmol). The mixture was cooled to 0 °C and added the DIAD (diisopropyl azodicarboxylate) (1.18 g, 5.86 mmol) dropwise over 5 minutes. The reaction mixture was stirred for 18 hours while warmed to room temperature. The reaction was quenched with water (2 ml) and concentrated to a residue, purified by silica gel chromatography with 20% EtOAc/Hexanes to afford product (1.05 g, 49%) and recovered starting material ((S)-2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester, 0.31 g).




(R,S)-3-[4-(1-Benzylloxycarbonyl-ethoxy)-phenyl]-2-ethoxy-propionic acid ethyl ester

To a solution of 2-(S)-hydroxypropionic acid benzyl ester (0.966 g, 5.36 mmol) and (S)-2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (1.16 g, 4.88 mmol) in THF (30 ml) was added the triphenyl phosphine (1.66 g, 6.34 mmol). The mixture was cooled to 0 °C and added the DIAD (diisopropyl azodicarboxylate) (1.18 g, 5.86 mmol) dropwise over 5 minutes. The reaction


mixture was stirred for 18 hours while warmed to room temperature. The reaction was quenched with water (2 ml) and concentrated to a residue, purified by silica gel chromatography with 20% EtOAc/Hexanes to afford product (1.05 g, 49%) and recovered starting material ((S)-2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester, 0.31 g).



**(R,S)-3-[4-(1-Carboxy-ethoxy)-phenyl]-2-ethoxy-propionic acid ethyl ester**



To a solution of (R,S)-3-[4-(1-benzyloxycarbonyl-ethoxy)-phenyl]-2-ethoxy-propionic acid ethyl ester (1.05 g, 2.63 mmol) in EtOH (20 ml) and H<sub>2</sub>O (0.5 ml) was added a slurry of Pd-C (5%, 100 mg) in EtOH (10 ml). The suspension was hydrogenated under balloon pressure for 2 hours. The mixture was filtered through a pad of celite and concentrated to a residue, the residue was then purified by silica gel chromatography with EtOAc/Hexanes (25% to 100%) to afford the acid product (550 mg, 68%).



## Example 73

(R,S)-3-(4-{1-[2-(3-Chloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid (

5 A solution of (R,S)-3-[4-(1-carboxy-ethoxy)-phenyl]-2-

ethoxy-propionic acid ethyl ester (310 mg, 1.00 mmol) in

CH<sub>2</sub>Cl<sub>2</sub> (35 ml) was treated with DMAP (207 mg, 1.70 mmol) and

EDC (286 mg, 1.50 mmol). The mixture was stirred at room

temperature for 10 minutes and then treated with 3-

10 chlorophenyl ethylamine (201 mg, 1.3 mmol). The reaction

mixture was stirred for 2 hours and quenched with NH<sub>4</sub>Cl

(aq), extracted with CH<sub>2</sub>Cl<sub>2</sub> (2x35 ml) and dried over Na<sub>2</sub>SO<sub>4</sub>

, purified on silica gel column with EtOAc/Hexanes (20-35%)

to yield the intermediate ester product (291 mg, 65%).

15 The ethyl ester was then dissolved in methanol (2.0 ml)

and THF (1.0 ml), and the solution was treated with NaOH

(2.0 N, 3.0 ml). The reaction mixture was stirred at room

temperature for 18 hours and neutralized with HCl (1.0 N,


6.0 ml) to pH=7 and concentrated. Extracted with EtOAc

20 (3x20 ml), dried over Na<sub>2</sub>SO<sub>4</sub>, purified on silica gel column

with EtOAc/Hexanes (35%-100%) and MeOH/EtOAc (5%) to yield

the final acid product (130 mg, 29% for two steps).


50350102-051902



**(S,S)-3-[4-(1-tert-Butoxycarbonyl-ethoxy)-phenyl]-2-ethoxy-propionic acid ethyl ester**


To a solution of 2-(R)-hydroxypropionic acid *tert*-butyl ester (1.23 g, 8.44 mmol) and (S)-2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (2.01 g, 8.44 mmol) in THF (100 ml) was added the triphenyl phosphine (2.21 g, 8.44 mmol). The mixture was cooled to 0 °C and added the DIAD (diisopropyl azodicarboxylate) (1.70 g, 8.44 mmol) dropwise over 5 minutes. The reaction mixture was stirred for 18 hours while warmed to room temperature. The reaction was quenched with water (2 ml) and concentrated to a residue, purified by silica gel chromatography with 20% EtOAc/Hexanes to afford product (0.99 g, 32%) and recovered starting material ((S)-2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester, 0.85 g).

**EXAMPLE 74**



**(S,S)-3-[4-(1-Carboxy-ethoxy)-phenyl]-2-ethoxy-propionic acid ethyl ester**

A solution of (S,S)-3-[4-(1-tert-butoxycarbonyl-ethoxy)-phenyl]-2-ethoxy-propionic acid ethyl ester (1.10 g, 3.00 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5.0 ml) and TFA (4.0 ml) and water (0.2 ml) was stirred for 12 hours. The mixture was concentrated to a residue and purified by silica gel chromatography with EtOAc/Hexanes (50%) to afford the acid product (0.91 g, 98%).



10

**Example 74A**

(S,S)-3-[4-{1-[2-(2-Chloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl]-2-ethoxy-

propionic acid

10 A solution of (S,S)-3-[4-(1-carboxy-ethoxy)-phenyl]-2-ethoxy-propionic acid ethyl ester (46.5 mg, 0.150 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 ml) was treated with DMAP (27 mg, 0.225 mmol) and  
5 EDC (43 mg, 0.225 mmol). The mixture was stirred at room temperature for 10 minutes and then treated with 2-chlorophenyl ethylamine (47 mg, 0.300 mmol). The reaction mixture was stirred for 2 hours and quenched with NH<sub>4</sub>Cl (aq), extracted with CH<sub>2</sub>Cl<sub>2</sub> (2x5 ml) and dried over Na<sub>2</sub>SO<sub>4</sub>,  
10 purified on silica gel column with EtOAc/Hexanes (25%) to yield the intermediate ester product.


15 The ethyl ester was then dissolved in methanol (0.5 ml) and THF (0.25 ml), and the solution was treated with NaOH (2.0 N, 0.5 ml). The reaction mixture was stirred at room temperature for 18 hours and neutralized with HCl (1.0 N, 1.0 ml) to pH=7 and concentrated. Extracted with EtOAc (3x2 ml), dried over Na<sub>2</sub>SO<sub>4</sub>, purified on silica gel column with EtOAc/Hexanes (35%-100%) and MeOH/EtOAc (5%) to yield the final acid product (23 mg, 37% for two steps).

20 2-Ethoxy-3-{4-[1-(3-trifluoromethyl-phenylethylcarbamoyl)-ethoxy]-phenyl}-propionic acid,

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.07 (br s, 3 H), 1.46 (d, 3 H, J = 6.8 Hz), 2.80-3.01 (m, 4 H), 3.28-3.32 (m, 1 H), 3.48-3.58 (m, 3 H), 3.88 (br s, 1H), 4.58 (q, 1 H, J = 6.4 Hz),

6.57-6.71 (m, 1 H), 6.73 (d, 2 H,  $J = 7.8$  Hz), 6.98-7.18 (m, 5 H), 7.28 (d, 1 H,  $J = 7.8$  Hz).

MS (MH<sup>+</sup>): 420.2





#### Example 75

#### 2-Ethoxy-3-[4-(1-hexylcarbamoyl-ethoxy)-phenyl]-propionic acid

The title compound was prepared using same method for (S,S)-3-(4-{1-[2-(2-Chloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid. <sup>1</sup>HNMR (400 MHz, CDCl<sub>3</sub>):

$\delta$  0.84 (t, 3 H,  $J = 6.8$  Hz), 1.17 (t, 3 H,  $J = 6.7$  Hz), 1.22-1.27 (m, 8 H), 1.44 (t, 2 H,  $J = 6.8$  Hz), 1.54 (d, 3 H,  $J = 6.8$  Hz), 2.93-2.98 (dd, 1 H,  $J = 7.3$  Hz, 13.7 Hz), 3.04-3.08 (dd, 1 H,  $J = 4.2$  Hz, 14.3 Hz), 3.41-3.46 (m, 1 H), 3.58-3.64 (m, 1 H), 4.03 (dd, 1 H,  $J = 4.4$  Hz, 7.8 Hz), 4.64 (q, 1H,  $J = 6.8$  Hz), 6.46 (t, 1 H,  $J = 5.4$  Hz), 6.82 (d, 2 H,  $J = 8.3$  Hz), 7.18 (d, 2 H,  $J = 8.8$  Hz),


MS (MH<sup>+</sup>): 366.2




## Example 76

3-{4-[1-(4-tert-Butyl-cyclohexylcarbamoyl)-ethoxy]-phenyl}-  
2-ethoxy-propionic acid

- 5 The title compound was prepared using same method for (S,S)-  
3-(4-{1-[2-(2-Chloro-phenyl)-ethylcarbamoyl]-ethoxy}-  
phenyl)-2-ethoxy-propionic acid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>,  
major isomer): δ 0.81 (s, 9H), 0.88-0.98 (m, 3 H), 1.05-1.17  
(m, 6 H), 1.51 (d, 3 H, J = 6.8 Hz), 1.70-1.88 (m, 3 H),  
10 1.98-2.01 (m, 1 H), 2.84-2.90 (dd, 1 H, J = 7.3 Hz, 13.7  
Hz), 2.99-3.04 (dd, 1 H, J = 4.2 Hz, 14.3Hz), 3.31 (br s, 1  
H), 3.54-3.57 (m, 1 H), 3.64-3.72 (m, 1 H), 3.95 (br s, 1  
H), 4.60 (q, 1H, J = 6.8 Hz), 6.27 (d, 1 H, J = 8.3 Hz),  
6.82 (d, 2 H, J = 8.3 Hz), 7.18 (d, 2 H, J = 7.8 Hz),  
15 MS (MH<sup>+</sup>): 420.3





## Example 77


2-Ethoxy-3-{4-[1-(3-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid


The title compound was prepared using same method for (S,S)-

5 3-(4-{1-[2-(2-Chloro-phenyl)-ethylcarbamoyl]-ethoxy}-

phenyl)-2-ethoxy-propionic acid.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$

1.07 (t, 3 H,  $J = 6.7$  Hz), 1.52 (d, 3 H,  $J = 6.8$  Hz), 2.82-  
2.89 (dd, 1 H,  $J = 7.3$  Hz, 13.7 Hz), 2.95-3.02 (dd, 1 H,  $J =$   
4.2 Hz, 14.3 Hz), 3.27-3.30 (m, 1 H), 3.50-3.54 (m, 1 H),  
10 3.92 (dd, 1 H,  $J = 4.4$  Hz, 7.8 Hz), 4.47 (d, 2 H,  $J = 5.9$   
Hz), 4.64 (q, 2 H,  $J = 7.3$  Hz), 6.76 (d, 2 H,  $J = 7.3$  Hz),  
6.06-7.14 (m, 3 H), 7.32-7.46 (m, 4 H); MS ( $\text{MH}^+$ ): 440.2.







## Example 78

2-Ethoxy-3-{4-[1-(5-fluoro-3-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid

- 5 The title compound was prepared using same method for (S,S)-3-(4-{1-[2-(2-Chloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  1.07 (t, 3 H,  $J = 6.7$  Hz), 1.53 (d, 3 H,  $J = 6.8$  Hz), 2.82-2.89 (dd, 1 H,  $J = 7.3$  Hz, 13.7 Hz), 2.95-3.02 (dd, 1 H,  $J = 4.2$  Hz, 14.3 Hz), 3.27-3.35 (m, 1 H), 3.53-3.58 (m, 1 H), 3.93 (dd, 1 H,  $J = 4.4$  Hz, 7.8 Hz), 4.40-4.50 (m, 2 H), 4.62 (q, 1 H,  $J = 6.8$  Hz), 6.76 (d, 2 H,  $J = 7.3$  Hz), 7.00 (d, 1 H,  $J = 8.8$  Hz), 7.13-7.20 (m, 5 H); MS ( $\text{MH}^+$ ): 486.1.




15



## Example 79

2-Ethoxy-3-{4-[1-(3-phenyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid

The title compound was prepared using same method for (S,S)-3-(4-{1-[2-(2-Chloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  1.02 (t, 3 H,  $J = 6.7$  Hz), 1.52 (d, 3 H,  $J = 6.8$  Hz), 2.78-2.84 (dd, 1 H,  $J = 7.3$  Hz, 13.7 Hz), 2.95-3.02 (dd, 1 H,  $J = 4.2$  Hz, 14.3 Hz), 3.22-3.27 (m, 1 H), 3.48-3.52 (m, 1 H), 3.89 (dd, 1 H,  $J = 4.4$  Hz, 7.8 Hz), 4.40-4.50 (m, 3 H), 6.75 (d, 2 H,  $J = 7.3$  Hz), 7.00 (br s, 1 H), 7.10 (d, 2 H,  $J = 7.8$  Hz), 7.28-7.49 (m, 9H); MS ( $\text{MH}^+$ ): 448.2.





#### 15 Example 80

2-Ethoxy-3-{4-[1-(4-phenoxy-phenylethylcarbamoyl)-ethoxy]-phenyl}-propionic acid

The title compound was prepared using same method for (S,S)-3-(4-{1-[2-(2-Chloro-phenyl)-ethylcarbamoyl]-ethoxy}-

phenyl)-2-ethoxy-propionic acid.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  1.16 (t, 3 H,  $J = 6.7$  Hz), 1.52 (d, 3 H,  $J = 6.8$  Hz), 2.65-2.71 (dd, 1 H,  $J = 6.9$  Hz, 13.7 Hz), 2.74-2.80 (dd, 1 H,  $J = 6.3$  Hz, 12.7 Hz), 2.96-2.99 (m, 1 H), 3.04-3.08 (m, 1 H), 3.40-3.44 (m, 2H), 3.56-3.64 (m, 2H), 4.03 (br s, 1H), 4.60 (q, 1 H,  $J = 6.4$  Hz), 6.48 (br s, 1H), 6.76 (d, 2 H,  $J = 7.8$  Hz), 6.85-6.88 (m, 2H), 6.96-7.00 (m, 4H), 7.07-7.17 (m, 3H), 7.30-7.35 (m, 2H); MS ( $\text{MH}^+$ ): 506.2.





### Example 81

2-Ethoxy-3-{4-[1-(3-trifluoromethyl-phenylethylcarbamoyl)-ethoxy]-phenyl}-propionic acid

The title compound was prepared using same method for (S,S)-3-(4-{1-[2-(2-chloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  1.00 (br s, 3 H), 1.43 (d, 3 H,  $J = 6.8$  Hz), 2.73-2.88 (m, 3 H), 2.96-3.00 (m, 1 H), 3.21-3.26 (m, 1 H), 3.46-3.52 (m, 3 H), 3.88 (br s, 1H), 4.60 (q, 1 H,  $J = 6.4$  Hz), 6.63-6.69

(m, 3 H), 7.10 (d, 1 H,  $J = 7.8$  Hz), 7.20 (d, 1 H,  $J = 7.8$  Hz), 7.29-7.36 (m, 2H), 7.42 (d, 1 H,  $J = 7.8$  Hz); MS (MH<sup>+</sup>): 454.2.

5





### Example 82

3-(4-{1-[2-(2,6-Dichloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid

The title compound was prepared using same method for (S,S)-3-(4-{1-[2-(2-Chloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.05 (t, 3 H,  $J = 6.4$  Hz), 1.45 (d, 3 H,  $J = 6.8$  Hz), 2.80-2.86 (dd, 1 H,  $J = 6.9$  Hz, 13.7 Hz), 2.97-3.01 (d, 1 H,  $J = 13.2$  Hz), 3.10-3.18 (m, 2 H), 3.22-3.30 (m, 1 H), 3.46-3.62 (m, 3 H), 3.92 (br s, 1H), 4.56 (q, 1 H,  $J = 6.4$  Hz), 6.71-6.77 (m, 3 H), 7.05 (t, 1 H,  $J = 7.8$  Hz), 7.12 (d, 2 H,  $J = 7.8$  Hz), 7.22 (d, 2 H,  $J = 7.8$  Hz); MS (MH<sup>+</sup>): 454.1

206130-201609



10



## Example 83

2-Ethoxy-3-(4-{1-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid

The title compound was prepared using same method for (S,S)-3-(4-{1-[2-(2-Chloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  1.16 (t, 3 H,  $J = 6.8$  Hz), 1.21 (t, 3 H,  $J = 7.6$  Hz), 1.49 (d, 3 H,  $J = 6.4$  Hz), 2.60 (q, 2 H,  $J = 6.8$  Hz), 2.60-2.68 (m, 1 H), 2.73-2.80 (m, 1 H), 2.94-3.00 (dd, 1 H,  $J = 7.8$  Hz, 14.2 Hz), 3.04-3.09 (dd, 1 H,  $J = 4.3$  Hz, 14.2 Hz), 3.40-3.46 (m, 2 H), 3.52-3.65 (m, 2 H), 4.03 (dd, 1 H,  $J = 4.3$  Hz, 7.8 Hz), 4.62 (q, 1 H,  $J = 6.8$  Hz), 6.52 (t, 1 H,  $J = 6.4$  Hz), 6.76 (d, 2 H,  $J = 8.8$  Hz), 6.95 (d, 2 H,  $J = 7.8$  Hz), 7.06 (d, 2 H,  $J = 7.8$  Hz), 7.18 (d, 2 H,  $J = 8.3$  Hz); MS (MH $^+$ ): 414.2.



#### Example 84

2-Ethoxy-3-(4-{1-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid

The title compound was prepared using same method for (S,S)-3-(4-{1-[2-(2-Chloro-phenyl)-ethylcarbamoyl]-ethoxy}-

phenyl)-2-ethoxy-propionic acid.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$

0.97 (t, 3 H,  $J = 7.8$  Hz), 1.19 (t, 3 H,  $J = 7.6$  Hz), 1.21 (t, 3 H,  $J = 6.8$  Hz), 1.80-1.90 (m, 1 H), 1.90-1.98 (m, 1H),

2.60 (q, 2 H,  $J = 7.3$  Hz), 2.60-2.68 (m 1 H), 2.72-2.79 (m, 1 H), 2.99 (dd, 1 H,  $J = 7.3$  Hz, 14.2 Hz), 3.08 (dd, 1 H,  $J$



= 3.9 Hz, 12.7 Hz), 3.40-3.48 (m, 2 H), 3.52-3.64 (m, 2 H),

4.02-4.07 (m, 1 H), 4.48 (dd, 1 H,  $J = 4.8$  Hz, 6.8 Hz), 6.54

(t, 1 H,  $J = 6.4$  Hz), 6.60 (d, 2 H,  $J = 8.8$  Hz), 6.87 (d, 2

H,  $J = 8.3$  Hz), 6.96 (d, 2 H,  $J = 7.8$  Hz), 7.02 (d, 2 H,  $J =$

8.3 Hz); MS ( $\text{MH}^+$ ): 428.2.



## Example 85

2-Ethoxy-3-(4-{1-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-propoxy}-phenyl)-propionic acid

The title compound was prepared using same method for (S,S)-3-(4-{1-[2-(2-Chloro-phenyl)-ethylcarbamoyl]-ethoxy}-

phenyl)-2-ethoxy-propionic acid.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$

0.80 (t, 3 H,  $J = 6.8$  Hz), 1.03 (t, 3 H,  $J = 7.6$  Hz), 1.10-

1.20 (m, 11 H), 2.85-2.89 (m, 1 H), 2.91 (dd, 1 H,  $J = 7.3$


Hz, 14.2 Hz), 2.98 (dd, 1 H,  $J = 4.8$  Hz, 14.2 Hz), 2.96-3.01


(m, 1 H), 3.37-3.43 (m, 2 H), 3.50-3.57 (m, 2 H), 3.99 (dd,

1 H,  $J = 4.4$  Hz, 7.3 Hz), 4.52 (t, 1 H,  $J = 6.4$  Hz), 6.54

(t, 1 H,  $J = 6.4$  Hz), 6.68 (d, 2 H,  $J = 8.3$  Hz), 7.02 (d, 2

H,  $J = 8.3$  Hz); MS (MH $^+$ ): 380.2






## Example 86

## 2-Ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-propoxy}-phenyl)-propionic acid

- 5 The title compound was prepared using same method for (S,S)-3-(4-{1-[2-(2-Chloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, one diastereomer): δ 0.92 (t, 3 H, *J* = 7.3 Hz), 1.10 (t, 3 H, *J* = 6.8 Hz), 1.74-1.82 (m, 1 H), 1.86-1.891 (m, 1 H), 2.56-2.62 (m, 1 H), 2.64-2.71 (m, 1 H), 2.86 (dd, 1 H, *J* = 7.3 Hz, 14.2 Hz), 2.98 (dd, 1 H, *J* = 4.4 Hz, 14.2 Hz), 3.33-3.40 (m, 2 H), 3.49-3.57 (m, 2 H), 3.95-3.99 (m, 1 H), 4.41 (dd, 1 H, *J* = 4.4 Hz, 6.8 Hz), 6.40 (t, 1 H, *J* = 6.4 Hz), 6.70 (d, 2 H, *J* = 8.3 Hz), 6.78 (d, 2 H, *J* = 8.8 Hz), 6.88-6.94 (m, 4 H), 7.01-7.06 (m, 1 H), 7.08 (d, 2 H, *J* = 8.8 Hz), 7.25 (d, 1 H, *J* = 7.4 Hz), 7.27 (d, 1 H, *J* = 7.8 Hz); MS (MH<sup>+</sup>): 492.1.





## Example 87

## 3-(4-{Cyclohexyl-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-methoxy}-phenyl)-2-ethoxy-propionic acid

5 The title compound was prepared using same method for (S,S)-  
3-(4-{1-[2-(2-Chloro-phenyl)-ethylcarbamoyl]-ethoxy}-  
phenyl)-2-ethoxy-propionic acid.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$   
1.16 (t, 3 H,  $J = 7.8$  Hz), 1.20 (t, 3 H,  $J = 7.6$  Hz), 1.20-  
1.30 (m, 6 H), 1.49 (d, 3 H,  $J = 6.8$  Hz), 2.08 (s, 2 H),  
10 2.60 (q, 2 H,  $J = 7.3$  Hz), 2.64-2.69 (m 1 H), 2.72-2.80 (m,  
1 H), 2.97 (dd, 1 H,  $J = 6.4$  Hz, 14.2 Hz), 3.08 (dd, 1 H,  $J$   
= 4.4 Hz, 14.2 Hz), 3.38-3.48 (m, 2 H), 3.52-3.66 (m, 2 H),  
3.80-3.90 (m, 1 H), 4.02 (dd, 1 H,  $J = 4.4$  Hz, 7.8 Hz), 4.62  
(q, 1 H,  $J = 6.9$  Hz), 4.93-5.02 (m, 1 H), 6.53 (t, 1 H,  $J =$   
15 5.9 Hz), 6.76 (d, 2 H,  $J = 8.8$  Hz), 6.95 (d, 2 H,  $J = 8.3$   
Hz), 7.07 (d, 2 H,  $J = 7.8$  Hz), 7.17 (d, 2 H,  $J = 8.3$  Hz); MS  
( $\text{MH}^+$ ): 483.2.

20






## Example 88


## 2-Ethoxy-3-(4-{1-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-2-phenyl-ethoxy}-phenyl)-propionic acid

5 The title compound was prepared using same method for (S,S)-  
 3-(4-{1-[2-(2-Chloro-phenyl)-ethylcarbamoyl]-ethoxy}-  
 phenyl)-2-ethoxy-propionic acid.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$   
 1.16 (t, 3 H,  $J = 7.8$  Hz), 1.21 (t, 3 H,  $J = 7.3$  Hz), 2.55-  
 2.65 (m, 4 H), 2.96 (dd, 1 H,  $J = 8.3$  Hz, 14.2 Hz), 3.04  
 10 (dd, 1 H,  $J = 3.9$  Hz, 14.2 Hz), 3.12 (dd, 1 H,  $J = 6.8$  Hz,  
 14.2 Hz), 3.24 (dd, 1 H,  $J = 3.4$  Hz, 14.2 Hz), 3.39-3.45 (m,  
 3 H), 3.59-3.65 (m, 1 H), 4.02 (dd, 1 H,  $J = 4.4$  Hz, 7.8  
 Hz), 4.62 (q, 1 H,  $J = 3.4$  Hz), 6.40 (t, 1 H,  $J = 5.8$  Hz),  
 6.69 (d, 2 H,  $J = 8.8$  Hz), 6.86 (d, 2 H,  $J = 7.8$  Hz), 7.04  
 15 (d, 2 H,  $J = 8.3$  Hz), 7.13 (d, 2 H,  $J = 8.8$  Hz), 7.20-7.30  
 (m, 5 H); MS ( $M+H$ ): 491.4.


Example 89: 2-Bromo-N-[2-(4-phenoxy-phenyl)-ethyl]-acetamide

4-phenoxyphenethylamine (213.28 amu, 2.5g, 1eq, 10.8mmol,  
 20 1.09 g/mL, 2.3mL) added to a 3-necked flask. Bromoacetyl

bromide (201.86 amu, 1.1eq, 11.8mmol, 2.4g, 2.317 g/mL, 1.03mL), pyridine (79.10 amu, 5 eq, 4.27 g, .978 g/mL, 54 mmol, 4.4 mL) added along with 50 mL CH<sub>2</sub>Cl<sub>2</sub>. Reaction stirred for 2 hours at RT. CH<sub>2</sub>Cl<sub>2</sub> removed and mixture taken up in 200mL EtOAc. Organic layer washed with brine and water (200mL each). Organics separated, dried sodium sulfate, and rotovaped to give 1.56g material. MS [EI+] 334 (M+H)<sup>+</sup>, MS [EI-] 332 (M-H)<sup>+</sup>




Example 90: 2-Methyl-2-phenoxy-3-(4-{[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-methoxy}-phenyl)-propionic acid



15


3-(4-Hydroxy-phenyl)-2-methyl-2-phenoxy-propionic acid ethyl ester (300.352amu, 1eq, 225mg, 0.76mmol) added to a 3-necked flask. 20mL dry dioxane added along with sodium hydride (24amu, 1.1eq, 0.82mmol, 20mg, 33mg of 60% dispersion in mineral oil). Mixture stirred at RT for 15 minutes. 2-Bromo-N-[2-(4-phenoxy-phenyl)-ethyl]-acetamide (333.1 amu, 250mg, 1eq, 0.76mmol) added and reaction stirred for 6 hours at 100degC. Reaction mixture added to 200mL EtOAc. Washed with brine and water (twice each, 200mL). Organics dried sodium sulfate and concentrated to give 250mg of crude material. Material separated on chromatatron (10-70%

EtOAc/hexanes). Product spot isolated and concentrated to give 25mg of desired ethyl ester. Material dissolved in 5mL EtOH. Added to a carousel tube along with 5mL 5N NaOH. Stirred overnight at 50°C under nitrogen. Reaction mixture  
 5 added to 100mL EtOAc. Acidified with 10mL concentrated HCl. 100mL brine added and organic layer removed. Concentrated to give 20mL product. MS [EI+] 526 (M+H)<sup>+</sup>, MS [EI-] 524 (M-H)<sup>+</sup>




Example 91:

2-Phenoxy-2-(4-{[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-methoxy}-benzyl)-butyric acid



15


The title compound was prepared using same method for 2-Methyl-2-phenoxy-3-(4-{[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-methoxy}-phenyl)-propionic acid from 2-(4-Hydroxy-benzyl)-2-phenoxy-butyric acid ethyl ester  
 20 MS [EI+] 540 (M+H)<sup>+</sup>, MS [EI-] 538 (M-H)<sup>+</sup>

Example 92

2-Methyl-3-(4-{[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-methoxy}-phenyl)-2-(4-trifluoromethoxy-phenoxy)-propionic acid


The title compound was prepared using same method for 2-Methyl-2-phenoxy-3-(4-{[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-methoxy}-phenyl)-propionic acid from 3-(4-Hydroxy-phenyl)-2-methyl-2-(4-trifluoromethoxy-phenoxy)-propionic acid ethyl ester.

MS [EI+] 610 (M+H)<sup>+</sup>, MS [EI-] 608 (M-H)<sup>+</sup>

Example 93

2-(4-Fluoro-phenoxy)-2-methyl-3-(4-{[2-(4-phenoxy-phenyl)-

ethylcarbamoyl]-methoxy}-phenyl)-propionic acid




ethylcarbamoyl]-methoxy}-phenyl)-propionic acid

The title compound was prepared using same method for 2-Methyl-2-phenoxy-3-(4-{[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-methoxy}-phenyl)-propionic acid from 2-(4-Fluoro-phenoxy)-3-(4-hydroxy-phenyl)-2-methyl-propionic acid ethyl ester.


MS [EI+] 544 (M+H)<sup>+</sup>, MS [EI-] 542 (M-H)<sup>+</sup>

Example 94

(2S)-2-methoxy-3-(4-{2-oxo-2-[4-(4-trifluoromethyl-phenyl)-piperazin-1-yl]-ethoxy}-phenyl)-propionic acid




Step 1: (2S)-3-(4-tert-butoxycarbonylmethoxy-phenyl)-2-methoxy-propionic acid ethyl ester



5 The compound of (2S)-3-(4-hydroxy-phenyl)-2-methoxy-propionic acid ester (example 1, step 1), (1.2 g, 5.3 mmol) was dissolved in 25 ml of anhydrous THF and NaH ( 380 mg, 15.8 mmol) was added portion wise. After about 5 minutes, bromo-acetic acid tert-butyl ester was added dropwise at room temperature. The mixture was stirred for 2 hours at room temperature. The crude was dissolved in ethyl acetate (100 ml) and a solution of 5% HCl was added. The mixture was extracted with ethyl acetate (3 X 100 ml), and the combined organic layers were dried over (MgSO<sub>4</sub>) and then concentrated under vacuum. The crude was purified by column chromatography (silica gel, hexane/ethyl acetate 8.5: 1,5) to afford a yellow oil.


Step 2: (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester



20 The compound of (2S)-3-(4-tert-butoxycarbonylmethoxy-phenyl)-2- methoxy-propionic acid ethyl ester (PREPARATION 3, step 1) (1.2 gr, 3.5 mmol) was solved in dichloromethane (5 ml) and trifluoroacetic acid was added (5 ml). The mixture was stirred for an hour, and the crude was concentrated to afford a yellow oil. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 200.15 MHz): 7.16 (d, 2H, J = 8.3), 6.75 (d, 2H, J = 8.3), 4.89 (s,

2H), 4.14 (c, 2H, J = 6.9), 3.94 (t, 1H, J = 6.9), 3.57 (dc, 1H), 3.35 (dc, 1H), 2.92 (d, 2H, J = 6.9), 1.23-1.10 (2t, 6H).


- 5 Step 3: (2S)-2-methoxy-3-(4-{2-oxo-2-[4-(4-trifluoromethyl-phenyl)-piperazin-1-yl]-ethoxy}-phenyl)-propionic acid



10 The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 1-(4-trifluoromethyl-phenyl)-piperazine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  
15 C<sub>23</sub>H<sub>25</sub>F<sub>3</sub>NO<sub>5</sub> [M+H]<sup>+</sup>: 467.

#### EXAMPLE 95

(2S)-3-(4-{[(biphenyl-4-ylmethyl)-carbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid




20

The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and C-biphenyl-4-yl-methylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-  
25

ethoxy}-phenyl)propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{25}H_{25}NO_5$   $[M+H]^+$ : 420.

## EXAMPLE 96


(2S)-2-methoxy-3-{4-[(methyl-naphthalen-1-ylmethyl-carbamoyl)-methoxy]-phenyl}-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and methyl-naphthalen-1-ylmethyl-amine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{24}H_{25}NO_5$   $[M+H]^+$ : 408.

## EXAMPLE 97


(2S)-3-{4-[2-(4-benzhydryl-piperazin-1-yl)-2-oxo-ethoxy]-phenyl}-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 1-benzhydryl-piperazine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{29}H_{32}N_2O_5$   $[M+H]^+$ : 489.

## EXAMPLE 98


(2S)-3-[4-(2-{4-[bis-(4-fluoro-phenyl)-methyl]-piperazin-1-yl}-2-oxo-ethoxy)-phenyl]-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 1-[bis-4-fluoro-phenyl]-methyl-piperazine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{29}H_{30}F_2N_2O_5$   $[M+H]^+$ : 525.

## EXAMPLE 99

(2S)-2-methoxy-3-(4-{[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-methoxy}-phenyl)-propionic acid




The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 2-(4-phenoxy-phenyl)-ethylamine via the same procedure used for the preparation of (2S, 1R)-

2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{26}H_{27}NO_6$   $[M+H]^+$ : 450.

5

## EXAMPLE 100


(2S)-3-{4-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxo-ethoxy]-phenyl}-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 1,2,3,4-tetrahydro-isoquinoline via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a yellow oil. MS (ES) for  $C_{21}H_{23}NO_5$   $[M+H]^+$ : 370.

## EXAMPLE 101

(2S)-3-{4-[(benzyl-phenethyl-carbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid




The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and benzyl-phenethyl-amine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-

206T90:20F06E09

ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a yellow oil. MS (ES) for  $C_{27}H_{29}NO_5$   $[M+H]^+$ : 448

## EXAMPLE 102


(2S)-3-(4-{2-[4-(4-fluoro-phenyl)-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 1-(4-fluoro-phenyl)-piperazine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{22}H_{25}FN_2O_5$   $[M+H]^+$ : 417.

## EXAMPLE 103


(2S)-2-methoxy-3-4-{[2-(2-methoxy-phenyl)-ethylcarbamoyl]-methoxy}-phenyl)-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 1-(4-chloro-phenyl)-2-methyl-piperazine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a yellow oil. MS (ES) for  $C_{23}H_{27}ClN_2O_5$   $[M+H]^+$ : 447.

## EXAMPLE 104


5 (2S)-3-(4-{2-[4-(3-chloro-phenyl)-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-2-methoxy-propionic acid



ES0390102-061902  
206190-201902  
10 The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 1-(3-chloro-phenyl)-piperazine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a yellow oil. MS (ES) for  $C_{22}H_{25}ClN_2O_5$   $[M+H]^+$ : 433.

## EXAMPLE 105


15 (2S)-3-(4-{2-[4-(4-chloro-benzyl)-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-2-methoxy-propionic acid



20 The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 1-(4-chloro-benzyl)-piperazine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{23}H_{27}ClN_2O_5$   $[M+H]^+$ : 447.

## EXAMPLE 106


(2S)-3-(4-{2-[4-(2-fluoro-phenyl)-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 1-(2-fluoro-phenyl)-piperazine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a yellow oil. MS (ES) for  $C_{22}H_{25}FN_2O_5$   $[M+H]^+$ : 417.

## EXAMPLE 106A


(2S)-3-(4-{[(benzo[1,3]dioxol-5-ylmethyl)-carbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and C-benzo[1,3]dioxol-5-yl-methylamine via the same procedure used for the preparation of (2S, 1R)-2-Ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{20}H_{21}NO_7$   $[M+H]^+$ : 388.

## EXAMPLE 106B


(2S)-3-(4-{[2-(4-bromo-phenyl)-ethylcarbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 2-(4-bromo-phenyl)-ethylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{20}H_{22}BrNO_5$   $[M+H]^+$ : 437.

## EXAMPLE 107


(2S)-2-methoxy-3-(4-{[(naphthalen-1-ylmethyl)-carbamoyl]-methoxy}-phenyl)-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and C-naphthalen-1-yl-methylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{23}H_{23}NO_5$   $[M+H]^+$ : 394.

## EXAMPLE 108


(2S)-3-(4-{[2-(2,6-dichloro-benzylsulfanyl)-ethylcarbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and C-naphthalen-1-yl-methylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a yellow oil. MS (ES) for  $C_{21}H_{23}Cl_2NO_5S$   $[M+H]^+$ : 473.

### EXAMPLE 109


(2S)-3-(4-{[benzyl-(1-phenyl-ethyl)-carbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid



15 The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and (1-phenyl-ethyl)-(2-vinyl-hexa-2,4-dienyl)-amine via the same procedure used for the  
20 preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{27}H_{29}NO_5$   $[M+H]^+$ : 448.

### EXAMPLE 110


25 (2S)-3-(4-(2-(4-(4-acetyl-phenyl)-piperazin-1-yl)-2-oxo-ethoxy)-phenyl)-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 1-(4-piperazin-1-yl-phenyl)-ethanone via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{24}H_{28}N_2O_6$   $[M+H]^+$ : 441.

## EXAMPLE 111

(2S)-2-methoxy-3-{4-[2-oxo-2-(4-p-tolyl-piperazin-1-yl)-ethoxy]-phenyl}-propionic acid




The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 1-p-tolyl-piperazine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a yellow oil. MS (ES) for  $C_{23}H_{28}N_2O_5$   $[M+H]^+$ : 413.

## EXAMPLE 112

(2S)-3-(4-{[ethyl-(2-fluoro-benzyl)-carbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid


60390102-061902



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and ethyl-(2-fluoro-benzyl)-amine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{21}H_{24}FNO_5$   $[M+H]^+$ : 390.

#### EXAMPLE 113


(2S)-3-(4-{[ethyl-(3-methyl-benzyl)-carbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and ethyl-(3-methyl-benzyl)-amine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{22}H_{27}NO_5$   $[M+H]^+$ : 386.

#### EXAMPLE 114


(2S)-3-(4-{2-[4-(4-fluoro-benzyl)-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 1-(4-fluoro-benzyl)-piperazine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{23}H_{27}FN_2O_5$   $[M+H]^+$ : 431.

## EXAMPLE 115

(2S)-3-{4-[(6-fluoro-benzothiazol-2-ylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid




The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 6-fluoro-benzothiazol-2-ylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{19}H_{17}FN_2O_5S$   $[M+H]^+$ :

405.

## EXAMPLE 116


(2S)-3-(4-{[2-(ethyl-m-tolyl-amino)-ethylcarbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and N1-ethyl-N1-m-tolyl-ethane-1,2-diamine via the same procedure used for the preparation of  
 5 (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{23}H_{30}N_2O_5$   $[M+H]^+$ : 414.

## EXAMPLE 117


10 (2S)-2-methoxy-3-{4-[(2-pyridin-2-yl-ethylcarbamoyl)-methoxy]-phenyl}-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 2-pyridin-2-yl-ethylamine via  
 15 the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{19}H_{22}N_2O_5$   $[M+H]^+$ : 359.

## EXAMPLE 118

20 (2S)-2-methoxy-3-{4-[(2-pyridin-3-yl-ethylcarbamoyl)-methoxy]-phenyl}-propionic acid




The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester  
 25

2005190-2010609

(PREPARATION 3, step 2) and 2-pyridin-3-yl-ethylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{19}H_{22}N_2O_5$   $[M+H]^+$ : 359.

## EXAMPLE 119


(2S)-E-3-{4-[(4-tert-butyl-cyclohexylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and E-4-tert-butyl-cyclohexylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{22}H_{33}NO_5$   $[M+H]^+$ : 392.

## EXAMPLE 120

(2S)-Z-3-{4-[(4-tert-butyl-cyclohexylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid




The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and Z-4-tert-butyl-cyclohexylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-

ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{22}H_{33}NO_5$   $[M+H]^+$ : 392.

## EXAMPLE 121


5 (2S)-3-(4-cyclobutylcarbamoylmethoxy-phenyl)-2-methoxy-propionic acid



10 The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and cyclobutylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{16}H_{21}NO_5$   $[M-H]^-$ : 306.

## EXAMPLE 122

15 (2S)-3-{4-[(1,3-dimethyl-butylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid




20 The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 1,3-dimethyl-butylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-

2006190102.061902

ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{18}H_{27}NO_5$   $[M-H]^-$ : 336.

## EXAMPLE 123


- 5 (2S)-2-methoxy-3-{4-[(1-methyl-hexylcarbamoyl)-methoxy]-phenyl}-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 1-methyl-hexylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{19}H_{29}NO_5$   $[M-H]^-$ : 350.

## EXAMPLE 124

- (2S)-2-methoxy-3-{4-[(1-methyl-butylcarbamoyl)-methoxy]-phenyl}-propionic acid



- 20 The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 1-methyl-butylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-


2025102-061902

(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{17}H_{25}NO_5$   $[M-H]^-$ : 322.

5

## EXAMPLE 125

(2S)-2-methoxy-3-{4-[(3-methyl-butylcarbamoyl)-methoxy]-phenyl}-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 3-methyl-butylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{17}H_{25}NO_5$   $[M-H]^-$ : 322.

## EXAMPLE 126

(2S)-3-(4-cyclopentylcarbamoylmethoxy-phenyl)-2-methoxy-propionic acid


20

The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and cyclopentylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{17}H_{23}NO_5$   $[M-H]^-$ : 320.

25

## EXAMPLE 127


(2S)-2-methoxy-3-{4-[(1-methyl-3-phenyl-propylcarbamoyl)-methoxy]-phenyl}-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 1-methyl-3-phenyl-propylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{22}H_{27}NO_5$   $[M-H]^-$ : 384.

## EXAMPLE 128


(2S)-3-{4-[(2,2,3,3,4,4,4-heptafluoro-butylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and nonafluorobutylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{16}H_{16}F_7NO_5$   $[M-H]^-$ : 434.

## EXAMPLE 129


(2S)-3-{4-[(5-tert-butyl-[1,3,4]thiadiazol-2-ylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 5-tert-butyl-[1,3,4]thiadiazol-2-ylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{18}H_{23}N_3O_5S$   $[M-H]^-$ : 392.

#### EXAMPLE 130


(2S)-3-{4-[(5-tert-butyl-[1,3,4]thiadiazol-2-ylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 5-tert-butyl-[1,3,4]thiadiazol-2-ylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{18}H_{23}N_3O_5S$   $[M-H]^-$ : 392.

#### EXAMPLE 131


(2S)-3-{4-[(4-tert-butyl-thiazol-2-ylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 4-tert-butyl-3H-1,4-thiazol-2-ylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{19}H_{24}N_2O_5S$   $[M-H]^-$ : 391.

## EXAMPLE 132


3-{4-[(5-cyclopropyl-[1,3,4]thiadiazol-2-ylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 5-cyclopropyl-[1,3,4]thiadiazol-2-ylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{17}H_{19}N_3O_5S$   $[M-H]^-$ : 376.

## EXAMPLE 133


(2S)-3-(4-hexylcarbamoylmethoxy-phenyl)-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and hexylamine via the same procedure used for the preparation of (2S, 1R)-2-Ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{18}H_{27}NO_5$   $[M-H]^-$ : 338.

EXAMPLE 134


(2S)-3-(4-heptylcarbamoylmethoxy-phenyl)-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and heptylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{19}H_{29}NO_5$   $[M-H]^-$ : 352.

EXAMPLE 135


(2S)-3-{4-[(3,3-dimethyl-butylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid



The title compound was prepared from (2S)-3-(4-carboxymethoxy-phenyl)-2-methoxy-propionic acid ethyl ester (PREPARATION 3, step 2) and 3,3-dimethyl-butylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{18}H_{27}NO_5$   $[M-H]^-$ : 338.

## EXAMPLE 136


3-{3-[(4-cis-tert-butyl-cyclohexylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid (isomer 1)



The title compound was prepared from 3-(3-carboxymethoxy-phenyl)-2-methoxy-propionic acid methyl ester (PREPARATION 4, step 2) and 4-cis-tert-butyl-cyclohexylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{22}H_{33}NO_5$   $[M+H]^+$ : 392.

## EXAMPLE 137


3-{3-[(4-trans-tert-butyl-cyclohexylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid (isomer 2)



The title compound was prepared from 3-(3-carboxymethoxy-phenyl)-2-methoxy-propionic acid methyl ester (PREPARATION 4, step 2) and 4-trans-tert-butyl-cyclohexylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{22}H_{33}NO_5$   $[M+H]^+$ : 392.

## EXAMPLE 138

3-(4-heptylcarbamoylmethoxy-phenyl)-2-methoxy-2-methyl-propionic acid



The title compound was prepared from 3-(4-carboxymethoxy-phenyl)-2-methoxy-2-methyl-propionic acid methyl ester heptylamine via the same procedure used for the preparation of (2S, 1R)-2-ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid (Example 1, step 3) to produce a colorless oil. MS (ES) for  $C_{20}H_{31}NO_5$   $[M+H]^+$ : 366.

## Biological Assays

Binding and Cotransfection Studies

The in vitro potency of compounds in modulating PPAR $\gamma$  and PPAR $\alpha$  receptors were determined by the procedures detailed below. DNA-dependent binding (ABCD binding) was

carried out using SPA technology with PPAR receptors. Tritium-labeled PPAR $\alpha$  and PPAR $\gamma$  agonists were used as radioligands for generating displacement curves and IC<sub>50</sub> values with compounds of the invention. Cotransfection assays were carried out in CV-1 cells. The reporter plasmid contained an acylCoA oxidase (AOX) PPRE and TK promoter upstream of the luciferase reporter cDNA. Appropriate PPARs and RXR $\alpha$  were constitutively expressed using plasmids containing the CMV promoter. For PPAR $\alpha$  and PPAR $\beta$ , interference by endogenous PPAR $\gamma$  in CV-1 cells was an issue. In order to eliminate such interference, a GAL4 chimeric system was used in which the DNA binding domain of the transfected PPAR was replaced by that of GAL4, and the GAL4 response element was utilized in place of the AOX PPRE. Cotransfection efficacy was determined relative to PPAR $\alpha$  agonist and PPAR $\gamma$  agonist reference molecules. Efficacies were determined by computer fit to a concentration-response curve, or in some cases at a single high concentration of agonist (10  $\mu$ M). For binding or cotransfection studies with receptors other than PPARs, similar assays were carried out using appropriate ligands, receptors, reporter constructs, etc., for that particular receptor.

These studies were carried out to evaluate the ability of compounds of the invention to bind to and/or activate various nuclear transcription factors, particularly huPPAR $\alpha$  ("hu" indicates "human") and huPPAR $\gamma$ . These studies provide in vitro data concerning efficacy and selectivity of compounds of the invention. Furthermore, binding and cotransfection data for compounds of the invention were compared with corresponding data for marketed compounds that act on either huPPAR $\alpha$  or huPPAR $\gamma$ .

Binding and cotransfection data for representative compounds of the invention were compared with corresponding data for reference to determine the binding.

5       The binding and cotransfection efficacy values found, for compounds of the invention and compounds of this invention which are useful for modulating a PPAR alpha receptor, were  $\leq 100$  nM and  $\geq 50\%$ , respectively. When coagonist modulators are desired, the values may be  
10 balanced against selectivity for the gamma or another desired PPAR receptor subtype.

Evaluation of Triglyceride Reduction and HDL Cholesterol  
Elevation in HuapoAI Transgenic Mice

15       Seventeen different series of studies were performed to evaluate the effect of compounds of the present invention upon HDL and triglyceride levels in human apoAI mice. For each compound tested, seven to eight week old male mice, transgenic for human apoAI (C57BL/6-tgn(apoal)1rub, Jackson  
20 Laboratory, Bar Harbor, ME) were acclimated in individual cages for two weeks with standard chow diet (Purina 5001) and water provided ad libitum. After the acclimation, mice and chow were weighed and assigned to test groups (n = 5) with randomization by body weight. Mice were dosed daily by  
25 oral gavage for 8 days using a 29 gauge, 1-1/2 inch curved feeding needle (Popper & Sons). The vehicle for the controls, test compounds and the positive control (fenofibrate 100mg/kg) was 1% carboxymethylcellulose (w/v) with 0.25% tween 80 (w/v). All mice were dosed daily  
30 between 6 and 8 a.m. with a dosing volume of 0.2ml. Prior to termination, animals and diets were weighed and body weight change and food consumption were calculated. Three

hours after last dose, mice were euthanized with CO<sub>2</sub> and blood was removed (0.5-1.0 ml) by cardiac puncture. After sacrifice, the liver, heart, and epididymal fat pad were excised and weighed. Blood was permitted to clot and serum  
5 was separated from the blood by centrifugation.

Cholesterol and triglycerides were measured colorimetrically using commercially prepared reagents (for example, as available from Sigma #339-1000 and Roche #450061 for triglycerides and cholesterol, respectively). The  
10 procedures were modified from published work (McGowan M. W. et al., Clin Chem 29:538-542,1983; Allain C. C. et al., Clin Chem 20:470-475,1974. Commercially available standards for triglycerides and total cholesterol, respectively, commercial quality control plasma, and samples were measured  
15 in duplicate using 200 µl of reagent. An additional aliquot of sample, added to a well containing 200 µl water, provided a blank for each specimen. Plates were incubated at room temperature on a plate shaker and absorbance was read at 500 nm and 540 nm for total cholesterol and triglycerides,  
20 respectively. Values for the positive control were always within the expected range and the coefficient of variation for samples was below 10%. All samples from an experiment were assayed at the same time to minimize inter-assay variability.

25 Serum lipoproteins were separated and cholesterol quantitated by fast protein liquid chromatography (FPLC) coupled to an in line detection system. Samples were applied to a Superose 6 HR size exclusion column (Amersham Pharmacia Biotech) and eluted with phosphate buffered  
30 saline-EDTA at 0.5 ml/min. Cholesterol reagent (Roche Diagnostics Chol/HP 704036) at 0.16ml/min mixed with the column effluent through a T-connection and the mixture

passed through a 15 m x 0.5 mm id knitted tubing reactor immersed in a 37 C water bath. The colored product produced in the presence of cholesterol was monitored in the flow stream at 505 nm and the analog voltage from the monitor was converted to a digital signal for collection and analysis. The change in voltage corresponding to change in cholesterol concentration was plotted vs time and the area under the curve corresponding to the elution of very low density lipoprotein (VLDL), low density lipoprotein (LDL) and high density lipoprotein (HDL) was calculated using Perkin Elmer Turbochrome software. The results of these studies are provided in the following tables for triglyceride and HDL cholesterol levels. Note that the superscripted numbers in the following tables refer to the study numbers. Further, the values, determined in each study, for triglyceride levels in the control mice and for HDL cholesterol levels in fenofibrate-treated mice are also provided in the following tables.

Triglyceride Serum Levels in Mice Dosed with a Compound of the Invention was Compared to Mice Receiving the Vehicle to identify compounds which could be particularly useful for lowering triglycerides. Generally, triglyceride decreases of greater than or equal to 30% (thirty percent) compared to control following a 30 mg/kg dose suggests a compound that can be especially useful for lowering triglyceride levels.

The percent increase of HDLc serum levels in mice receiving a compound of the invention was compared to mice receiving vehicle to identify compounds of the invention that could be particularly useful for elevating HDL levels. Generally, an increase of greater than or equal to 25% (twenty five percent) increase in HDLc level following a 30

206T90"20T06C09  
60390102-051902

mg/kg dose suggests a compound that can be especially useful for elevating HDLc levels.

It may be particularly desirable to select compounds of this invention that both lower triglyceride levels and  
5 increase HDLc levels. However, compounds that either lower triglyceride levels or increase HDLc levels may be desirable as well.

#### Evaluation of Glucose Levels in db/db Mice

10 The effects, upon plasma glucose of administering various dose levels of five different compounds of the present invention and the PPAR gamma agonist rosiglitazone (BRL49653) or the PPAR alpha agonist fenofibrate, and the control, to male db/db mice, were studied.

15 Five week old male diabetic (db/db) mice [for example, C57BlKs/j-m +/+ Lepr(db), Jackson Laboratory, Bar Harbor, ME] or lean littermates were housed 6 per cage with food and water available at all times. After an acclimation period of 2 weeks, animals were individually identified by ear  
20 notches, weighed, and bled via the tail vein for determination of initial glucose levels. Blood was collected (100 µl) from unfasted animals by wrapping each mouse in a towel, cutting the tip of the tail with a scalpel, and milking blood from the tail into a heparinized  
25 capillary tube. Sample was discharged into a heparinized microtainer with gel separator and retained on ice. Plasma was obtained after centrifugation at 4°C and glucose measured immediately. Remaining plasma was frozen until the completion of the experiment, when glucose and triglycerides  
30 were assayed in all samples. Animals were grouped based on initial glucose levels and body weights. Beginning the following morning, mice were dosed daily by oral gavage for

7 days. Treatments were test compounds (30 mg/kg), a positive control agent (30 mg/kg) or vehicle [1% carboxymethylcellulose (w/v)/ 0.25% Tween80 (w/v); 0.3 ml/mouse]. On day 7, mice were weighed and bled (tail vein) 3 hours after dosing. Twenty-four hours after the 7<sup>th</sup> dose (i.e., day 8), animals were bled again (tail vein). Samples obtained from conscious animals on days 0, 7 and 8 were assayed for glucose. After the 24 hour bleed, animals were weighed and dosed for the final time. Three hours after dosing on day 8, animals were anesthetized by inhalation of isoflurane and blood obtained via cardiac puncture (0.5-0.7 ml). Whole blood was transferred to serum separator tubes, chilled on ice and permitted to clot. Serum was obtained after centrifugation at 4°C and frozen until analysis for compound levels. After sacrifice by cervical dislocation, the liver, heart and epididymal fat pads were excised and weighed.

Glucose was measured colorimetrically using commercially purchased reagents. According to the manufacturers, the procedures were modified from published work (McGowan, M. W., Artiss, J. D., Strandbergh, D. R. & Zak, B. Clin Chem, 20:470-5 (1974) and Keston, A. Specific colorimetric enzymatic analytical reagents for glucose. Abstract of papers 129th Meeting ACS, 31C (1956).); and depend on the release of a mole of hydrogen peroxide for each mole of analyte, coupled with a color reaction first described by Trinder (Trinder, P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem, 6:24 (1969)). The absorbance of the dye produced is linearly related to the analyte in the sample. The assays were further modified in our laboratory for use in a 96 well format. The commercially available

standard for glucose, commercially available quality control plasma, and samples (2 or 5 µl/well) were measured in duplicate using 200 µl of reagent. An additional aliquot of sample, pipetted to a third well and diluted in 200 µl water, provided a blank for each specimen. Plates were incubated at room temperature for 18 minutes for glucose on a plate shaker (DPC Micormix 5) and absorbance read at 500 nm on a plate reader. Sample absorbances were compared to a standard curve (100-800 for glucose). Values for the quality control sample were always within the expected range and the coefficient of variation for samples was below 10%. All samples from an experiment were assayed at the same time to minimize inter-assay variability.

The results of the study, suggest compounds of the present invention that significantly reduced db/db mouse plasma glucose levels while resulting in body weight gains that were less than those observed for rosiglitazone.

Evaluation of the Effects of Compounds of the Present Invention upon A<sup>y</sup> Mice Body Weight, Fat Mass, Glucose and Insulin Levels

Female A<sup>y</sup> Mice

Female A<sup>y</sup> mice were singly housed, maintained under standardized conditions (22°C, 12 h light:dark cycle), and provided free access to food and water throughout the duration of the study. At twenty weeks of age the mice were randomly assigned to vehicle control and treated groups based on body weight and body fat content as assessed by DEXA scanning (N=6). Mice were then dosed via oral gavage with either vehicle or a Compound of this invention (50 mg/kg) one hour after the initiation of the light cycle (for

example, about 7 A.M.) for 18 days. Body weights were measured daily throughout the study. On day 14 mice were maintained in individual metabolic chambers for indirect calorimetry assessment of energy expenditure and fuel  
5 utilization. On day 18 mice were again subjected to DEXA scanning for post treatment measurement of body composition.

The results of p.o. dosing of compound for 18 days on body weight, fat mass, and lean mass were evaluated and suggest which compounds of this invention can be especially  
10 useful for maintaining desirable weight and/or promoting desired lean to fat mass.

Indirect calorimetry measurements revealed a significant reduction in respiratory quotient (RQ) in treated animals during the dark cycle [ $0.864 \pm 0.013$   
15 (Control) vs.  $0.803 \pm 0.007$  (Treated);  $p < 0.001$ ]. This reduction in RQ is indicative of an increased utilization of fat during the animals' active (dark) cycle. Additionally, treated animals displayed significantly higher rates of energy expenditure than control animals ( $17.40 \pm 0.49$  vs.  
20  $13.62 \pm 0.26$  kcal/kg/hr, respectively).

#### Male KK/A<sup>y</sup> Mice

Male KK/A<sup>y</sup> mice were singly housed, maintained under standardized conditions (22°C, 12 h light:dark cycle), and  
25 provided free access to food and water throughout the duration of the study. At twenty-two weeks of age the mice were randomly assigned to vehicle control and treated groups based on plasma glucose levels. Mice were then dosed via oral gavage with either vehicle or a Compound of this  
30 invention (30 mg/kg) one hour after the initiation of the light cycle (7 A.M.) for 14 days. Plasma glucose, triglyceride, and insulin levels were assessed on day 14.

60390102 "061902  
206130" 201005E09

The results of p.o. dosing of compound for 14 days on plasma glucose, triglycerides, and insulin are evaluated to identify compounds of this invention which may be especially desired.

5

Method to Elucidate the LDL-cholesterol Total-cholesterol and Triglyceride Lowering Effect of Compound 5(8)

10

Male Syrian hamsters (Harlan Sprague Dawley) weighing 80-120 g were placed on a high-fat cholesterol-rich diet for two to three weeks prior to use. Feed and water were provided ad libitum throughout the course of the experiment. Under these conditions, hamsters became hypercholesterolemic showing plasma cholesterol levels between 180-280 mg/dl.

15

(Hamsters fed with normal chow had a total plasma cholesterol level between 100-150 mg/dl.) Hamsters with high plasma cholesterol (180 mg/dl and above) were randomized into treatment groups based on their total cholesterol level using the GroupOptimizeV211.xls program.

20

A Compound of this invention was dissolved in an aqueous vehicle (containing CMC with Tween 80) such that each hamster received once a day approx. 1 ml of the solution by gavage at doses 3 and 30 mg/kg body weight. Fenofibrate (Sigma Chemical, prepared as a suspension in the same vehicle) was given as a known alpha-agonist control at a dose of 200 mg/kg, and the blank control was vehicle alone. Dosing was performed daily in the early morning for 14 days.

25

Quantification of Plasma Lipids :

30

On the last day of the test, hamsters were bled (400 ul) from the suborbital sinus while under isoflurane anesthesia 2 h after dosing. Blood samples were collected into heparinized microfuge tubes chilled in ice bath. Plasma

samples were separated from the blood cells by brief centrifugation. Total cholesterol and triglycerides were determined by means of enzymatic assays carried out automatically in the Monarch equipment (Instrumentation Laboratory) following the manufacturer's procedure. Plasma lipoproteins (VLDL, LDL and HDL) were resolved by injecting 25 ul of the pooled plasma samples into an FPLC system eluted with phosphate buffered saline at 0.5 ml/min through a Superose 6 HR 10/30 column (Pharmacia) maintained room temp. Detection and characterization of the isolated plasma lipids were accomplished by postcolumn incubation of the effluent with a Cholesterol/HP reagent (for example, Roche Lab System; infused at 0.12 ml/min) in a knitted reaction coil maintained at 37°C. The intensity of the color formed was proportional to the cholesterol concentration and was measured photometrically at 505 nm.

The effect of administration of a Compound of this invention for 14 days is studied for the percent reduction in LDL level with reference to the vehicle group. The LDL-lowering efficacy for certain compounds of this invention is markedly more potent than that of fenofibrate. Compounds of this invention that decrease LDL greater than or equal to 30% (thirty percent) compared to vehicle can be especially desired.

The total-cholesterol and triglyceride lowering effects of a Compound of this invention was also studied. The data for reduction in total cholesterol and triglyceride levels after treatment with a compound of this invention for 14 days was compared to the vehicle to suggest compounds that can be particularly desired. The known control fenofibrate did not show significant efficacy under the same experimental conditions.

Method to Elucidate the Fibrinogen-Lowering Effect of  
PPAR Modulators

5 Zucker Fatty Rat Model:

10 The life phase of the study on fibrinogen-lowering effect of  
compounds of this invention was part of the life phase  
procedures for the antidiabetic studies of the same  
15 compounds. On the last (14<sup>th</sup>) day of the treatment period,  
with the animals placed under surgical anesthesia, ~ 3ml of  
blood is collected, by cardiac puncture, into a syringe  
containing citrate buffer. The blood sample is chilled  
and centrifuged at 4°C to isolate the plasma that was stored  
at -70 °C prior to fibrinogen assay.

2005F90" 20T06E09  
60390102-061902

Quantification of Rat Plasma Fibrinogen:

5 Rat plasma fibrinogen levels were quantified by using a commercial assay system consists of a coagulation instrument following the manufacturer's protocol. In essence, 100 ul of plasma was sampled from each specimen and a 1/20 dilution is prepared with buffer. The diluted plasma is incubated at 37°C for 240 seconds. Fifty microliters of clotting reagent thrombin solution (provided by the instrument's manufacturer in a standard concentration) is then added. The instrument monitored the clotting time, a function of fibrinogen concentration quantified with reference to standard samples.

Results :

Compounds of this invention are capable of lowering fibrinogen level in vivo. Compounds that lower fibrinogen level greater than vehicle can be especially desired.

20 Cholesterol and triglyceride lowering effects of compounds of this invention were also produced in Zucker rats.

Method to Elucidate the Anti-body Weight Gain and Anti-appetite Effects of Compounds of this invention

25


Fourteen-Day Study in Zucker Fatty Rat<sup>1</sup> or ZDF Rat<sup>2</sup> Models :

Male Zucker Fatty rats, non-diabetic (Charles River Laboratories, Wilmington, MA) or male ZDF rats (Genetic Models, Inc, Indianapolis, IN) of comparable age and weight were acclimated for 1 week prior to treatment. Rats were on normal chow and water was provided ad libitum throughout the course of the experiment.


α-agonists were dissolved in an aqueous vehicle such that each rat received once a day approximately 1 ml of the solution by garvage at doses 0.1, 0.3, 1 and 3 mg/kg body weight. Fenofibrate (Sigma Chemical, prepared as a suspension in the same vehicle) a known alpha-agonist given at doses of 300 mg/kg, as well as the vehicle were controls. Dosing was performed daily in the early morning for 14 days. Over the course of the experiment, body weight and food consumption were monitored. Using this assay, compounds of this invention were found to result in significant weight reduction.

Certain Features of the present invention may be preferred for pharmaceutical use. The following embodiments of the present invention and characteristics of compounds within the scope of the present invention are listed in tabular form and one or more may be independently combined to provide a variety of desired compounds and embodiments of the present invention. The following tabular list of embodiments is illustrative of the present invention and is in no way intended to limit the scope of the claimed invention.


A) A compound of the formula:




B) A compound of the formula:




C) A compound of the formula:



D) A compound of the formula:



E) R2 is selected from the group consisting of




F) R2 is  $-\text{CH}(\text{C}(\text{O})\text{OCH}_3)\text{benzyl}$ ;

206190:20106E09

G) R6 is selected from the group consisting of, hydrogen, substituted C<sub>1</sub>-C<sub>4</sub> alkyl, unsubstituted C<sub>1</sub>-C<sub>4</sub> alkyl, substituted aryl-C<sub>0</sub>-4-alkyl, and unsubstituted aryl-C<sub>0</sub>-4-alkyl;

5 H) R5 is H or methyl.

I) A compound of the formula:



J) R6 is C<sub>1</sub>-C<sub>3</sub> alkyl;

K) R6 is methyl;

10 L) E is C(R3)(R4)A;

M) R5 is hydrogen or methyl;

N) R3 is C<sub>1</sub>-C<sub>3</sub>alkoxy;

O) E is C(R3)(R4)A and A is C(O)OR<sub>26</sub>; R<sub>26</sub> is H or C<sub>1</sub>-C<sub>3</sub>alkyl;

15 P) A compound which is selected from the group consisting of :

(2S,1'R)-2-Ethoxy-3-(4-{1'-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid; (2S,1'R)-2-Ethoxy-3-(4-{1'-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid; (2S,1'R)-2-ethoxy-3-(4-{1'-[2-(4-trifluoromethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid; (2S,1'R)-2-ethoxy-3-(4-{1'-[2-(2-ethoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid; (2S,1'R)-2-ethoxy-3-{4-[1'-(3-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid; (2S,1'R)-2-ethoxy-3-{4-[1'-(3-fluoro-5-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

(2S,1'R)-3-(4-{1'-[(biphenyl-3-ylmethyl)-carbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;  
(2S,1'R)-3-(4-{1'-[2-(3-chloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;  
(2S,1'R)-2-ethoxy-3-(4-{1'-[2-(3-fluoro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;  
(2S,1'R)-2-ethoxy-3-(4-{1'-[2-(2-fluoro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;  
(2S,1'R)-3-(4-{1'-[2-(2,4-dichloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;  
(2S,1'R)-3-(4-{1'-[2-(2,6-dichloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;  
(2S,1'R)-3-(4-{1'-[2-(2-chloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid; (2S,1'R)-3-(4-{1'-[2-(4-tert-butyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;  
(2S,1'R)-2-ethoxy-3-{4-[1'-(4-fluoro-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid; (2S,1'R)-2-ethoxy-3-{4-[1'-(4-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;  
(2S,1'R)-3-{4-[1'-(4-tert-butyl-benzylcarbamoyl)-ethoxy]-phenyl}-2-ethoxy-propionic acid; (2S,1'R)-3-{4-[1'-(4-tert-butyl-phenylcarbamoyl)-ethoxy]-phenyl}-2-ethoxy-propionic acid; (2S,1'R)-3-{4-[1'-(4-trans-tert-butyl-cyclohexylcarbamoyl)-ethoxy]-phenyl}-2-ethoxy-propionic acid;  
(2S)-3-{4-[1-(4-tert-butyl-cyclohexylcarbamoyl)-1-methyl-ethoxy]-phenyl}-2-methoxy-propionic acid;

(2S)-2-methoxy-3-(4-{1-methyl-1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S)-3-(4-{1-[2-(2-ethoxy-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

2-methoxy-3-(4-{1-methyl-1-[2-(3-trifluoromethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S)-2-methoxy-3-{4-[1-methyl-1-(3-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

(2S)-3-(4-{1-[2-(2-chloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-(4-{1-[(biphenyl-3-ylmethyl)-carbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-(4-{1-[2-(2,5-dimethoxy-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-(4-{1-[2-(2-fluoro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-2-ethoxy-3-(4-{1-methyl-1-[2-(3-trifluoromethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S)-2-ethoxy-3-{4-[1-(3-fluoro-5-trifluoromethyl-benzylcarbamoyl)-1-methyl-ethoxy]-phenyl}-propionic acid;

(2S)-3-(4-{1-[2-(2-chloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S)-3-(4-{1-[(biphenyl-3-ylmethyl)-carbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S)-3-(4-{1-[2-(3-chloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;

- (2S)-3-(4-{1-[2-(2,5-dimethoxy-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;
- 5 (2S)-2-ethoxy-3-(4-{1-[2-(2-fluoro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-propionic acid;
- (2S)-3-{3-[1-(4-tert-butyl-cyclohexylcarbamoyl)-1-methyl-ethoxy]-phenyl}-2-methoxy-propionic acid;
- 10 (2S)-3-{3-[1-(3-fluoro-5-trifluoromethyl-benzylcarbamoyl)-1-methyl-ethoxy]-phenyl}-2-methoxy-propionic acid;
- (2S)-3-(3-{1-[(biphenyl-3-ylmethyl)-carbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;
- 15 (2S)-3-(3-{1-[2-(3-chloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;
- (2S)-2-methoxy-3-{4-[(1-phenyl-ethylcarbamoyl)-methoxy]-phenyl}-propionic acid;
- 20 (2S)-3-(3-{1-[2-(2,4-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;
- (2S)-3-(3-{1-[2-(2,6-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;
- 25 (2S)-3-(4-{1-[2-(2,4-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;
- (2S)-3-(4-{1-[2-(2,4-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;
- 30 (2S)-3-(4-{1-[2-(2,6-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;

- (2S)-2-ethoxy-3-(4-{1-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-propionic acid;
- (2S)-2-ethoxy-3-(4-{1-[2-(2-ethoxy-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-propionic acid;
- 2-Ethoxy-3-{4-[1-(3-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;
- 2-Ethoxy-3-{4-[1-(5-fluoro-3-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;
- 2-Ethoxy-3-{4-[1-(3-phenyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;
- 2-Ethoxy-3-{4-[1-(4-phenoxy-phenylethylcarbamoyl)-ethoxy]-phenyl}-propionic acid;
- 2-Ethoxy-3-{4-[1-(3-trifluoromethyl-phenylethylcarbamoyl)-ethoxy]-phenyl}-propionic acid;
- 3-(4-{1-[2-(2,6-Dichloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;
- 2-Ethoxy-3-(4-{1-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;
- 2-Ethoxy-3-(4-{1-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;
- 3-(4-{Cyclohexyl-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-methoxy}-phenyl)-2-ethoxy-propionic acid;
- 2-Ethoxy-3-(4-{1-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-2-phenyl-ethoxy}-phenyl)-propionic acid; and
- (2S,1'R)-2-ethoxy-3-{4-[1'-(2-thiophen-2-yl-ethylcarbamoyl)-ethoxy]-phenyl}-propionic acid; and pharmaceutically acceptable salts thereof;
- Q) A compound selected from the group consisting of

(2S,1'R)-3-{4-[1'-(4-tert-butyl-cyclohexylcarbamoyl)-ethoxy]-phenyl}-2-ethoxy-propionic acid;

(2S,1'R)-2-ethoxy-3-(4-{1'-[(thiophen-2-ylmethyl)-carbamoyl]-ethoxy}-phenyl)-propionic acid;

5 (2S,1'R)-2-ethoxy-3-{4-[1'-(2-thiophen-2-yl-ethylcarbamoyl)-ethoxy]-phenyl}-propionic acid;  
and

pharmaceutically acceptable salts thereof;

10 R) A compound selected from the group consisting of  
(2S,1'R)-2-ethoxy-3-[4-(1'-heptylcarbamoyl-ethoxy)-phenyl]-propionic acid;

(2S)-3-[3-(1-heptylcarbamoyl-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid;

15 (2S)-2-ethoxy-3-[4-(1-heptylcarbamoyl-1-methyl-ethoxy)-phenyl]-propionic acid; 2-Ethoxy-3-(4-{1-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-propoxy}-phenyl)-propionic acid;

2-Ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-propoxy}-phenyl)-propionic acid; and

20 pharmaceutically acceptable salts thereof;

S) A compound selected from the group consisting of

(2S)-3-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-2-oxo-ethoxy}-phenyl)-2-methoxy-propionic acid;

25 (2S)-3-(4-{2-[4-(4-chloro-benzoyl)-piperidin-1-yl]-2-oxo-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-[4-(2-{4-[bis-(4-fluoro-phenyl)-methyl]-piperazin-1-yl}-2-oxo-ethoxy)-phenyl]-2-methoxy-propionic acid;

(2S)-3-(4-{2-[4-(2-fluoro-phenyl)-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-2-methoxy-propionic acid;

30 2S)-3-[4-(2-{4-[(4-chloro-phenyl)-phenyl-methyl]-piperazin-1-yl}-2-oxo-ethoxy)-phenyl]-2-methoxy-propionic acid;

(2S)-3-(4-{2-[4-(4-acetyl-phenyl)-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-2-methoxy-propionic acid;


(2S)-3-[4-(2-{4-[(4-chloro-phenyl)-phenyl-methyl]-piperazin-1-yl}-2-oxo-ethoxy)-phenyl]-2-methoxy-

5 propionic acid;

(2S)-3-{4-[2-(4-benzhydryl-piperazin-1-yl)-2-oxo-ethoxy]-phenyl}-2-methoxy-propionic acid;

(2S)-3-(4-{2-[4-(4-fluoro-benzyl)-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-2-methoxy-propionic acid;

10 (2S)-3-{4-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxo-ethoxy]-phenyl}-2-methoxy-propionic acid;



(2S)-3-(4-{2-[4-(4-fluoro-phenyl)-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-2-methoxy-propionic acid;

15 (2S)-2-methoxy-3-4-{[2-(2-methoxy-phenyl)-ethylcarbamoyl]-methoxy}-phenyl)-propionic acid;


(2S)-3-(4-{2-[4-(3-chloro-phenyl)-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-2-methoxy-propionic acid;

20 (2S)-3-(4-{2-[4-(4-chloro-benzyl)-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-2-methoxy-propionic acid; (2S)-2-methoxy-3-{4-[2-oxo-2-(4-p-tolyl-piperazin-1-yl)-ethoxy]-phenyl}-propionic acid;

25 (2S)-2-methoxy-3-(4-{2-oxo-2-[4-(4-trifluoromethyl-phenyl)-piperazin-1-yl]-ethoxy}-phenyl)-propionic acid; and a pharmaceutically acceptable salt thereof.

T) A compound selected from the group consisting of (2S)-3-(4-{[benzyl-(1-phenyl-ethyl)-carbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid

206190-20106009




- 5 (2S)-3-(4-{[ethyl-(2-fluoro-benzyl)-carbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid;
- (2S)-3-[4-({ethyl-[2-(4-methoxy-phenyl)-1-methyl-ethyl]-carbamoyl}-methoxy)-phenyl]-2-methoxy-propionic acid;
- (2S)-3-(4-{[ethyl-(3-methyl-benzyl)-carbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid;
- 10 (2S)-2-methoxy-3-{4-[(methyl-naphthalen-1-ylmethyl)-carbamoyl]-methoxy}-phenyl}-propionic acid;
- (2S)-3-(4-{[butyl-(1-phenyl-ethyl)-carbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid;
- 15 (2S)-3-(4-{[butyl-(1-phenyl-ethyl)-carbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid;
- (2S)-2-methoxy-3-(4-{[methyl-(1-phenyl-ethyl)-carbamoyl]-methoxy}-phenyl)-propionic acid;
- (2S)-3-(4-{[benzyl-(2-ethoxycarbonyl-ethyl)-carbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid; and
- 20 pharmaceutically acceptable salts there.
- (2S)-3-(4-{[benzyl-(2-ethoxycarbonyl-ethyl)-carbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid;
- S)-3-{4-[(benzyl-phenethyl-carbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid;
- 25 (2S)-2-methoxy-3-{4-[(1-methoxycarbonyl-2-phenyl-ethylcarbamoyl)-methoxy]-phenyl}-propionic acid;
- (2S)-3-(4-{[benzyl-(2-ethoxycarbonyl-ethyl)-carbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid;

- (2S)-3-(4-{[(benzo[1,3]dioxol-5-ylmethyl)-carbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid;
- (2S)-3-{4-[(6-fluoro-benzothiazol-2-ylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid;
- 5 (2S)-2-methoxy-3-{4-[(1-naphthalen-1-yl-ethylcarbamoyl)-methoxy]-phenyl}-propionic acid;
- (2S)-2-methoxy-3-(4-{[(naphthalen-1-ylmethyl)-carbamoyl]-methoxy}-phenyl)-propionic acid;
- 10 (2S)-3-(4-{[2-(2,6-dichloro-benzylsulfanyl)-ethylcarbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid;
- (2S)-3-[4-({[(4-chloro-phenyl)-phenyl-methyl]-carbamoyl]-methoxy)-phenyl]-2-methoxy-propionic acid;
- 15 (2S)-3-{4-[(3,3-diphenyl-propylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid;
- 2-methoxy-2-methyl-3-(4-{[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-methoxy}-phenyl)-propionic acid;
- (2S)-2-methoxy-3-(4-{[3-(methyl-phenyl-amino)-propylcarbamoyl]-methoxy}-phenyl)-propionic acid;
- 20 (2S)-2-methoxy-3-(4-{[3-(methyl-phenyl-amino)-propylcarbamoyl]-methoxy}-phenyl)-propionic acid;
- (2S)-2-methoxy-3-{4-[(1-methoxycarbonyl-2-phenyl-ethylcarbamoyl)-methoxy]-phenyl}-propionic acid;
- 25 (2S)-2-methoxy-3-{4-[(2-pyridin-2-yl-ethylcarbamoyl)-methoxy]-phenyl}-propionic acid;
- (2S)-E-3-{4-[(4-tert-butyl-cyclohexylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid;
- (2S)-Z-3-{4-[(4-tert-butyl-cyclohexylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid;
- 30 (2S)-3-(4-cyclobutylcarbamoylmethoxy-phenyl)-2-methoxy-propionic acid;

(2S)-2-methoxy-3-{4-[(1-methyl-3-phenyl-propylcarbamoyl)-methoxy]-phenyl}-propionic acid;  
(2S)-3-{4-[(5-tert-butyl- [1,3,4] thiadiazol-2-ylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic  
5 acid;  
(2S)-3-{4-[(5-tert-butyl- [1,3,4] thiadiazol-2-ylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic  
acid;  
(2S)-3-{4-[(4-tert-butyl-thiazol-2-ylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid;  
10 3-{4-[(5-cyclopropyl- [1,3,4] thiadiazol-2-ylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid;  
(2S)-2-methoxy-3-(4-{[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-methoxy}-phenyl)-propionic acid;  
15 (2S)-3-{4-[(1,3-dimethyl-butylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid;  
(2S)-2-methoxy-3-{4-[(1-methyl-hexylcarbamoyl)-methoxy]-phenyl}-propionic acid;  
(2S)-2-methoxy-3-{4-[(1-methyl-butylcarbamoyl)-methoxy]-phenyl}-propionic acid;  
20 (2S)-2-methoxy-3-{4-[(3-methyl-butylcarbamoyl)-methoxy]-phenyl}-propionic acid;  
(2S)-3-{4-[(2,2,3,3,4,4,4-heptafluoro-butylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid;  
25 (2S)-3-(4-cyclopentylcarbamoylmethoxy-phenyl)-2-methoxy-propionic acid;  
3-{3-[(4-cis-tert-butyl-cyclohexylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid; and  
pharmaceutically acceptable salts thereof;

20250901 09:01:00



- U) A compound ; and  
 pharmaceutically acceptable salts thereof;
- V) A compound that is the hemipiperazine salt;
- W) R5 is methyl and R6 is hydrogen;
- X) R1 is hydrogen;
- Y) R2 is substituted arylalkyl;
- Z) R2 is unsubstituted arylalkyl;
- AA) R2 is arylalkyl and the aryl group is phenyl;
- BB) E is C(R3)(R4)A, and R3 is hydrogen and R4 is  
 alkoxy;
- CC) R4 is ethoxy;
- DD) A is COOH;
- EE) R4 is halo, a substituted or unsubstituted group  
 selected from C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>1</sub>-C<sub>5</sub> alkoxy, C<sub>3</sub>-C<sub>6</sub>  
 cycloalkyl, aryl C<sub>0</sub>-C<sub>4</sub> alkyl, C<sub>1-4</sub>alkoxyaryl, and  
 phenyl, or R3 and R4 are combined to form a C<sub>3</sub>-C<sub>6</sub>  
 cycloalkyl;
- FF) R4 is a substituted or unsubstituted group selected  
 from C<sub>1</sub>-C<sub>5</sub> alkoxy, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, aryl C<sub>0</sub>-C<sub>4</sub>  
 alkyl, C<sub>1-4</sub>alkoxyaryl, and phenyl, or R3 and R4 are  
 combined to form a C<sub>3</sub>-C<sub>6</sub> cycloalkyl;
- GG) R2 is arylC<sub>2</sub>alkyl;
- HH) aryl is phenyl;
- II) A compound of this invention is formulated as a  
 tablet or capsule;
- JJ) A compound of this invention is used to treat  
 diabetes;
- KK) A compound of this invention is used to treat  
 Syndrome X;

LL) A compound of this invention is used to treat elevated lipids; and

MM) A compound of this invention is a pharmaceutically acceptable salt.

5

**EQUIVALENTS:**

While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.

10


2006T90"20T06E09  
60390102:061902

## CLAIMS

What is claimed is:

1. A Compound of the structural formula I:

Formula I



- (a) R1 is selected from the group consisting of hydrogen, substituted or unsubstituted group selected from C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, aryl-C<sub>0-4</sub>-alkyl, heteroaryl-C<sub>0-4</sub>-alkyl, aminoC<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkylaryl-C<sub>0-2</sub>-alkyl, arylheteroC<sub>1</sub>-C<sub>8</sub>alkyl, -CHC(O)C<sub>1</sub>-C<sub>4</sub>alkoxy; C<sub>0-4</sub>-alkyl-C(O)heteroC<sub>1</sub>-C<sub>8</sub>alkyl, and -CH<sub>2</sub>-C(O)-R15-R16, wherein R15 is O or NH and R16 is optionally substituted benzyl;
- (b) R2 is selected from the group consisting of substituted or unsubstituted group selected from C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, aryl-C<sub>0-4</sub>-alkyl, heteroaryl-C<sub>0-4</sub>-alkyl, aminoC<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkylaryl-C<sub>0-2</sub>-alkyl, arylheteroC<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>0-4</sub>-alkyl-C(O)heteroC<sub>1</sub>-C<sub>8</sub>alkyl, and -CH<sub>2</sub>-C(O)-R15-R16, wherein R15 is O or NH and R16 is optionally substituted benzyl;

- 5
- (c) R1 and R2 together may form a substituted or unsubstituted heterocyclic ring;
- (d) E is selected from the group consisting of C(R3)(R4)A, and a substituted or unsubstituted selected from the group consisting of (CH<sub>2</sub>)<sub>n</sub> COOR13, aryl-C<sub>0-4</sub>-alkyl, thio-C<sub>1-4</sub>-alkyl, thioaryl, C<sub>1-4</sub>alkoxyaryl, C<sub>1-4</sub>alkoxyC<sub>1-4</sub>alkyl, aminoaryl, and aminoC<sub>1-4</sub>alkyl;
- 10
- (e) n and m are each independently selected from the group consisting of 0, 1, 2 and 3;
- (f) A is an functional group selected from the group consisting of (CH<sub>2</sub>)<sub>m</sub> COOR14, C<sub>1-3</sub>alkylnitrile, carboxamide, substituted or unsubstituted sulfonamide, substituted or unsubstituted acylsulfonamide and substituted or unsubstituted tetrazole;
- 5
- (g) R3 is H, saturated or unsaturated C<sub>1-5</sub> alkyl, C<sub>1-5</sub> alkoxy;
- 20
- (h) R4 is H, halo, a substituted or unsubstituted group selected from C<sub>1-5</sub> alkyl, C<sub>1-5</sub> alkoxy, C<sub>3-6</sub> cycloalkyl, aryl C<sub>0-4</sub> alkyl, C<sub>1-4</sub>alkoxyaryl, and phenyl, or R3 and R4 are combined to form a C<sub>3-6</sub> cycloalkyl;
- 25
- (i) R5 and R6 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted group selected from C<sub>1-8</sub> alkyl, aryl-C<sub>0-4</sub>-alkyl, heteroaryl-C<sub>0-4</sub>-alkyl, C<sub>3-6</sub> cycloalkylaryl-
- 30

60390107-061902


C<sub>0-2</sub>-alkyl, C<sub>3-6</sub> cycloalkyl-C<sub>0-2</sub>-alkyl, and  
-CH<sub>2</sub>-C(O)-R<sub>17</sub>-R<sub>18</sub>;

(j) R<sub>17</sub> and R<sub>18</sub> are each independently selected  
from C<sub>1-8</sub> alkyl, aryl-C<sub>0-4</sub>-alkyl,  
heteroaryl-C<sub>0-4</sub>-alkyl, C<sub>3-6</sub> cycloalkylaryl-  
C<sub>0-2</sub>-alkyl, and C<sub>3-6</sub> cycloalkyl-C<sub>0-2</sub>-alkyl;

(k) R<sub>13</sub> and R<sub>14</sub> are each independently selected  
from the group consisting of hydrogen,  
optionally substituted C<sub>1-4</sub>alkyl and  
optionally substituted arylmethyl; and

pharmaceutically acceptable salts thereof.


2. A compound as claimed by Claim 1 of the structural  
Formula II:



wherein R<sub>19</sub> is selected from the group consisting of  
hydrogen, a substituted or unsubstituted group selected  
from the group consisting of C<sub>1-4</sub>alkyl, aryl, and  
arylmethyl;

and pharmaceutically acceptable salts thereof.


3. A compound as claimed by Claim 1 that is of the  
following structural formula III:



wherein R19 is selected from the group consisting of hydrogen, a substituted or unsubstituted group selected from the group consisting of C1-C4alkyl, aryl, and arylmethyl;


and pharmaceutically acceptable salts thereof.

4. A compound as claimed by Claim 1 that is of the structural formula IV:




wherein R11 is selected from the group consisting of aryl, substituted -C(O)aryl, -C(O)aryl, haloC<sub>1</sub>-C<sub>5</sub>alkyloxy, substituted aryl, C<sub>1</sub>-C<sub>5</sub> alkylaryl, substituted alkylaryl, C<sub>1</sub>-C<sub>5</sub> alkylbiaryl, substituted C<sub>1</sub>-C<sub>5</sub> alkylbiaryl, and alkyl; and pharmaceutically acceptable salts thereof.

5. A compound as claimed by Claim 1 that is of the structural formula V:



wherein R12 is selected from the group consisting of aryl, substituted -C(O)aryl, haloC<sub>1</sub>-C<sub>5</sub>alkyloxy, substituted aryl, C<sub>1</sub>-C<sub>5</sub> alkylaryl, substituted alkylaryl, C<sub>1</sub>-C<sub>5</sub> alkylbiaryl, substituted C<sub>1</sub>-C<sub>5</sub> alkylbiaryl, and alkyl; and pharmaceutically acceptable salts thereof.


6. A compound as claimed by Claim 1 that is of the structural formula VI:



VI

wherein R12 is selected from the group consisting of aryl, substituted -C(O)aryl, haloC<sub>1</sub>-C<sub>5</sub>alkyloxy, substituted aryl, C<sub>1</sub>-C<sub>5</sub> alkylaryl, substituted alkylaryl, C<sub>1</sub>-C<sub>5</sub> alkylbiaryl, substituted C<sub>1</sub>-C<sub>5</sub> alkylbiaryl, and alkyl; R25 is selected from the group consisting of alkyl, halo, haloalkyl, alkoxy, and phenyl; and pharmaceutically acceptable salts thereof.


7. A compound as claimed by Claim 1 that is of the structural formula VII:



VII

wherein R12 is selected from the group consisting of aryl, substituted -C(O)aryl, haloC<sub>1</sub>-C<sub>5</sub>alkyloxy, substituted aryl, C<sub>1</sub>-C<sub>5</sub> alkylaryl, substituted alkylaryl, C<sub>1</sub>-C<sub>5</sub> alkylbiaryl, substituted C<sub>1</sub>-C<sub>5</sub> alkylbiaryl, and alkyl; R21 is selected from the group consisting of phenyl, substituted phenyl, and C<sub>1</sub>-C<sub>6</sub> alkyl; and pharmaceutically acceptable salts thereof.

8. A compound as claimed by any one of Claims 1, 2, or 3 wherein R2 is a substituted or unsubstituted substituent selected from the group consisting of the formulas:



9. A compound as claimed by any one of Claims 1, 2, or 3 wherein R2 is -CH(C(O)OCH<sub>3</sub>)benzyl.

10. A compound as claimed by any one of Claims 1, 2, 3, 4, 5, 6, 7, 8, or 9 wherein R6 is selected from the group consisting of hydrogen, substituted C<sub>1</sub>-C<sub>4</sub> alkyl, unsubstituted C<sub>1</sub>-C<sub>4</sub> alkyl, substituted aryl-C<sub>0</sub>-4-alkyl, and unsubstituted aryl-C<sub>0</sub>-4-alkyl.

11. A compound as claimed by any one of Claims 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 wherein R5 is H or methyl.
12. A compound as claimed by any one of Claims 1, 2, 3, 4, 5, 6, 7, 8, or 9 wherein R6 is C<sub>1</sub>-C<sub>3</sub> alkyl.
- 5 13. A compound as claimed by any one of Claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 11 or 12 wherein R6 is methyl.
14. A compound as claimed by any one of Claims 1, 4, 5, 6, 8, 9, 10, 11, 12, or 13 wherein E is C(R3)(R4)A.
- 10 15. A compound as claimed by Claim 10 wherein R5 is hydrogen or methyl, R6 is C<sub>1</sub>-C<sub>3</sub> alkyl, and E is C(R3)(R4)A, and R3 is C<sub>1</sub>-C<sub>3</sub>alkoxy.
16. A compound as claimed by any one of Claims 1, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, or 15 wherein E is C(R3)(R4)A and A is C(O)OR<sub>26</sub>; R<sub>26</sub> is H or C<sub>1</sub>-C<sub>3</sub>alkyl.
- 5 17. A compound as claimed by Claim 1 which is selected from the group consisting of :
- (2S,1'R)-2-Ethoxy-3-(4-{1'-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid; (2S,1'R)-2-Ethoxy-3-(4-{1'-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid; (2S,1'R)-2-ethoxy-3-(4-{1'-[2-(4-trifluoromethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;
- 20 (2S,1'R)-2-ethoxy-3-(4-{1'-[2-(2-ethoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;
- 25 (2S,1'R)-2-ethoxy-3-{4-[1'-(3-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;
- (2S,1'R)-2-ethoxy-3-{4-[1'-(3-fluoro-5-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;
- 30 (2S,1'R)-3-(4-{1'-[(biphenyl-3-ylmethyl)-carbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;

205190:2070509

(2S,1'R)-3-(4-{1'-[2-(3-chloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S,1'R)-2-ethoxy-3-(4-{1'-[2-(3-fluoro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S,1'R)-2-ethoxy-3-(4-{1'-[2-(2-fluoro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S,1'R)-3-(4-{1'-[2-(2,4-dichloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S,1'R)-3-(4-{1'-[2-(2,6-dichloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S,1'R)-3-(4-{1'-[2-(2-chloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid; (2S,1'R)-3-(4-{1'-[2-(4-tert-butyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S,1'R)-2-ethoxy-3-{4-[1'-(4-fluoro-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid; (2S,1'R)-2-ethoxy-3-{4-[1'-(4-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid; (2S,1'R)-3-{4-[1'-(4-tert-butyl-benzylcarbamoyl)-ethoxy]-phenyl}-2-ethoxy-propionic acid; (2S,1'R)-3-{4-[1'-(4-tert-butyl-phenylcarbamoyl)-ethoxy]-phenyl}-2-ethoxy-propionic acid; (2S,1'R)-3-{4-[1'-(4-trans-tert-butyl-cyclohexylcarbamoyl)-ethoxy]-phenyl}-2-ethoxy-propionic acid;

(2S)-3-{4-[1-(4-tert-butyl-cyclohexylcarbamoyl)-1-methyl-ethoxy]-phenyl}-2-methoxy-propionic acid;

(2S)-2-methoxy-3-(4-{1-methyl-1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S)-3-(4-{1-[2-(2-ethoxy-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

2-methoxy-3-(4-{1-methyl-1-[2-(3-trifluoromethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S)-2-methoxy-3-{4-[1-methyl-1-(3-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

(2S)-3-(4-{1-[2-(2-chloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-(4-{1-[(biphenyl-3-ylmethyl)-carbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-(4-{1-[2-(2,5-dimethoxy-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-(4-{1-[2-(2-fluoro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-2-ethoxy-3-(4-{1-methyl-1-[2-(3-trifluoromethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S)-2-ethoxy-3-{4-[1-(3-fluoro-5-trifluoromethyl-benzylcarbamoyl)-1-methyl-ethoxy]-phenyl}-propionic acid;

(2S)-3-(4-{1-[2-(2-chloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S)-3-(4-{1-[(biphenyl-3-ylmethyl)-carbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S)-3-(4-{1-[2-(3-chloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;

- (2S)-3-(4-{1-[2-(2,5-dimethoxy-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;
- (2S)-2-ethoxy-3-(4-{1-[2-(2-fluoro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-propionic acid;
- (2S)-3-{3-[1-(4-tert-butyl-cyclohexylcarbamoyl)-1-methyl-ethoxy]-phenyl}-2-methoxy-propionic acid;
- (2S)-3-{3-[1-(3-fluoro-5-trifluoromethyl-benzylcarbamoyl)-1-methyl-ethoxy]-phenyl}-2-methoxy-propionic acid;
- (2S)-3-(3-{1-[(biphenyl-3-ylmethyl)-carbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;
- (2S)-3-(3-{1-[2-(3-chloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;
- (2S)-2-methoxy-3-{4-[(1-phenyl-ethylcarbamoyl)-methoxy]-phenyl}-propionic acid;
- (2S)-3-(3-{1-[2-(2,4-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;
- (2S)-3-(3-{1-[2-(2,6-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;
- (2S)-3-(4-{1-[2-(2,4-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-methoxy-propionic acid;
- (2S)-3-(4-{1-[2-(2,4-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;
- (2S)-3-(4-{1-[2-(2,6-dichloro-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-2-ethoxy-propionic acid;

(2S)-2-ethoxy-3-(4-{1-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-propionic acid;

(2S)-2-ethoxy-3-(4-{1-[2-(2-ethoxy-phenyl)-ethylcarbamoyl]-1-methyl-ethoxy}-phenyl)-propionic acid;

2-Ethoxy-3-{4-[1-(3-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

2-Ethoxy-3-{4-[1-(5-fluoro-3-trifluoromethyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

2-Ethoxy-3-{4-[1-(3-phenyl-benzylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

2-Ethoxy-3-{4-[1-(4-phenoxy-phenylethylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

2-Ethoxy-3-{4-[1-(3-trifluoromethyl-phenylethylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

3-(4-{1-[2-(2,6-Dichloro-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-2-ethoxy-propionic acid;

2-Ethoxy-3-(4-{1-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

2-Ethoxy-3-(4-{1-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-ethoxy}-phenyl)-propionic acid;

3-(4-{Cyclohexyl-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-methoxy}-phenyl)-2-ethoxy-propionic acid;

2-Ethoxy-3-(4-{1-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-2-phenyl-ethoxy}-phenyl)-propionic acid; and

(2S,1'R)-2-ethoxy-3-{4-[1'-(2-thiophen-2-yl-ethylcarbamoyl)-ethoxy]-phenyl}-propionic acid; and pharmaceutically acceptable salts thereof.

18. A compound as claimed by Claim 1 wherein the compound is selected from the group consisting of

(2S,1'R)-3-{4-[1'-(4-tert-butyl-cyclohexylcarbamoyl)-ethoxy]-phenyl}-2-ethoxy-propionic acid;

(2S,1'R)-2-ethoxy-3-(4-{1'-[(thiophen-2-ylmethyl)-carbamoyl]-ethoxy}-phenyl)-propionic acid;

(2S,1'R)-2-ethoxy-3-{4-[1'-(2-thiophen-2-yl-ethylcarbamoyl)-ethoxy]-phenyl}-propionic acid;

and

pharmaceutically acceptable salts thereof.

19. A compound as claimed by Claim 1 wherein the compound is selected from the group consisting of

(2S,1'R)-2-ethoxy-3-[4-(1'-heptylcarbamoyl-ethoxy)-phenyl]-propionic acid;

(2S)-3-[3-(1-heptylcarbamoyl-1-methyl-ethoxy)-phenyl]-2-methoxy-propionic acid;

(2S)-2-ethoxy-3-[4-(1-heptylcarbamoyl-1-methyl-ethoxy)-phenyl]-propionic acid; 2-Ethoxy-3-(4-{1-[2-(4-ethyl-phenyl)-ethylcarbamoyl]-propoxy}-phenyl)-propionic acid;

2-Ethoxy-3-(4-{1-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-propoxy}-phenyl)-propionic acid; and

pharmaceutically acceptable salts thereof.

20. A compound as claimed by Claim 1 wherein the compound is selected from the group consisting of

(2S)-3-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-2-oxo-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-(4-{2-[4-(4-chloro-benzoyl)-piperidin-1-yl]-2-oxo-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-[4-(2-{4-[bis-(4-fluoro-phenyl)-methyl]-piperazin-1-yl}-2-oxo-ethoxy)-phenyl]-2-methoxy-propionic acid;

(2S)-3-(4-{2-[4-(2-fluoro-phenyl)-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-[4-(2-{4-[(4-chloro-phenyl)-phenyl-methyl]-piperazin-1-yl}-2-oxo-ethoxy)-phenyl]-2-methoxy-propionic acid;


(2S)-3-(4-{2-[4-(4-acetyl-phenyl)-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-[4-(2-{4-[(4-chloro-phenyl)-phenyl-methyl]-piperazin-1-yl}-2-oxo-ethoxy)-phenyl]-2-methoxy-propionic acid;

(2S)-3-{4-[2-(4-benzhydryl-piperazin-1-yl)-2-oxo-ethoxy]-phenyl}-2-methoxy-propionic acid;

(2S)-3-(4-{2-[4-(4-fluoro-benzyl)-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-{4-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxo-ethoxy]-phenyl}-2-methoxy-propionic acid;



(2S)-3-(4-{2-[4-(4-fluoro-phenyl)-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-2-methoxy-3-4-{[2-(2-methoxy-phenyl)-ethylcarbamoyl]-methoxy}-phenyl)-propionic acid;

(2S)-3-(4-{2-[4-(3-chloro-phenyl)-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-2-methoxy-propionic acid;

(2S)-3-(4-{2-[4-(4-chloro-benzyl)-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-2-methoxy-propionic acid;


(2S)-2-methoxy-3-{4-[2-oxo-2-(4-p-tolyl-piperazin-1-yl)-ethoxy]-phenyl}-propionic acid;

(2S)-2-methoxy-3-(4-{2-oxo-2-[4-(4-trifluoromethyl-phenyl)-piperazin-1-yl]-ethoxy}-phenyl)-propionic acid; and

a pharmaceutically acceptable salt thereof.

206T90.20T06E09

21. A compound as claimed by Claim 1 wherein the compound is selected from the group consisting of (2S)-3-(4-{[benzyl-(1-phenyl-ethyl)-carbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid




- (2S)-3-(4-{[ethyl-(2-fluoro-benzyl)-carbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid;
- (2S)-3-[4-({ethyl-[2-(4-methoxy-phenyl)-1-methyl-ethyl]-carbamoyl}-methoxy)-phenyl]-2-methoxy-propionic acid;
- (2S)-3-(4-{[ethyl-(3-methyl-benzyl)-carbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid;
- (2S)-2-methoxy-3-{4-[(methyl-naphthalen-1-ylmethyl)-carbamoyl]-methoxy}-phenyl}-propionic acid;
- (2S)-3-(4-{[butyl-(1-phenyl-ethyl)-carbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid;
- (2S)-3-(4-{[butyl-(1-phenyl-ethyl)-carbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid;
- (2S)-2-methoxy-3-(4-{[methyl-(1-phenyl-ethyl)-carbamoyl]-methoxy}-phenyl)-propionic acid;
- (2S)-3-(4-{[benzyl-(2-ethoxycarbonyl-ethyl)-carbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid; and pharmaceutically acceptable salts there.
- (2S)-3-(4-{[benzyl-(2-ethoxycarbonyl-ethyl)-carbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid;
- S)-3-{4-[(benzyl-phenethyl)-carbamoyl]-methoxy}-phenyl}-2-methoxy-propionic acid;

- (2S)-2-methoxy-3-{4-[(1-methoxycarbonyl-2-phenyl-ethylcarbamoyl)-methoxy]-phenyl}-propionic acid;
- (2S)-3-(4-{[benzyl-(2-ethoxycarbonyl-ethyl)-carbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid;
- 5 (2S)-3-(4-{[(benzo[1,3]dioxol-5-ylmethyl)-carbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid;
- (2S)-3-{4-[(6-fluoro-benzothiazol-2-ylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid;
- (2S)-2-methoxy-3-{4-[(1-naphthalen-1-yl-ethylcarbamoyl)-methoxy]-phenyl}-propionic acid;
- 10 (2S)-2-methoxy-3-(4-{[(naphthalen-1-ylmethyl)-carbamoyl]-methoxy}-phenyl)-propionic acid;
- (2S)-3-(4-{[2-(2,6-dichloro-benzylsulfanyl)-ethylcarbamoyl]-methoxy}-phenyl)-2-methoxy-propionic acid;
- 5 (2S)-3-[4-({[(4-chloro-phenyl)-phenyl-methyl]-carbamoyl]-methoxy)-phenyl]-2-methoxy-propionic acid;
- (2S)-3-{4-[(3,3-diphenyl-propylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid;
- 20 2-methoxy-2-methyl-3-(4-{[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-methoxy}-phenyl)-propionic acid;
- (2S)-2-methoxy-3-(4-{[3-(methyl-phenyl-amino)-propylcarbamoyl]-methoxy}-phenyl)-propionic acid;
- 25 (2S)-2-methoxy-3-(4-{[3-(methyl-phenyl-amino)-propylcarbamoyl]-methoxy}-phenyl)-propionic acid;
- (2S)-2-methoxy-3-{4-[(1-methoxycarbonyl-2-phenyl-ethylcarbamoyl)-methoxy]-phenyl}-propionic acid;
- (2S)-2-methoxy-3-{4-[(2-pyridin-2-yl-ethylcarbamoyl)-methoxy]-phenyl}-propionic acid;
- 30 (2S)-E-3-{4-[(4-tert-butyl-cyclohexylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid;

- (2S)-Z-3-{4-[(4-tert-butyl-cyclohexylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid;
- (2S)-3-(4-cyclobutylcarbamoylmethoxy-phenyl)-2-methoxy-propionic acid;
- 5 (2S)-2-methoxy-3-{4-[(1-methyl-3-phenyl-propylcarbamoyl)-methoxy]-phenyl}-propionic acid;
- (2S)-3-{4-[(5-tert-butyl-[1,3,4]thiadiazol-2-ylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid;
- 10 (2S)-3-{4-[(5-tert-butyl-[1,3,4]thiadiazol-2-ylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid;
- (2S)-3-{4-[(4-tert-butyl-thiazol-2-ylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid;
- 15 3-{4-[(5-cyclopropyl-[1,3,4]thiadiazol-2-ylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid;
- (2S)-2-methoxy-3-(4-{[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-methoxy}-phenyl)-propionic acid;
- (2S)-3-{4-[(1,3-dimethyl-butylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid;
- 20 (2S)-2-methoxy-3-{4-[(1-methyl-hexylcarbamoyl)-methoxy]-phenyl}-propionic acid;
- (2S)-2-methoxy-3-{4-[(1-methyl-butylcarbamoyl)-methoxy]-phenyl}-propionic acid;
- 25 (2S)-2-methoxy-3-{4-[(3-methyl-butylcarbamoyl)-methoxy]-phenyl}-propionic acid;
- (2S)-3-{4-[(2,2,3,3,4,4,4-heptafluoro-butylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid;
- (2S)-3-(4-cyclopentylcarbamoylmethoxy-phenyl)-2-methoxy-propionic acid;
- 30 3-{3-[(4-cis-tert-butyl-cyclohexylcarbamoyl)-methoxy]-phenyl}-2-methoxy-propionic acid; and


pharmaceutically acceptable salts thereof.

23. A compound as claimed by Claim 1 wherein the compound is



; and pharmaceutically acceptable salts thereof.

24. A compound as claimed by Claim 1 wherein the compound



is ; and pharmaceutically acceptable salts thereof.

25. A compound as claimed by any one of Claims 1 through 24 which is the hemipiperazine salt.

26. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and at least one compound as claimed by any one of Claims 1-25 or a pharmaceutically acceptable salt thereof.

27. A method of modulating a peroxisome proliferator activated receptor, comprising the step of contacting the receptor with at least one compound as claimed by any one of Claims 1-25 or a pharmaceutically acceptable salt thereof.

28. A method of treating diabetes mellitus in a mammal, comprising the step of administering to the mammal a therapeutically effective amount of at least one compound of Claims 1-25 or a pharmaceutically acceptable salt thereof.

29. A method of preventing diabetes mellitus in a mammal, comprising the step of administering to the mammal an

effective amount of at least one compound of Claims 1-25 or a pharmaceutically acceptable salt thereof.

30. A method of treating Syndrome X in a mammal, comprising the step of administering to the mammal a therapeutically effective amount of at least one compound of Claims 1-25, or a pharmaceutically acceptable salt thereof.

31. Use of a compound for the manufacture of a medicament

for the treatment of a condition modulated by a peroxisome proliferator activated receptor, wherein the compound, or pharmaceutically acceptable salt thereof, is a compound of Claims 1-25.


32. A compound as disclosed by any one of the examples herein.

5  
10  
5  
20661902 051902

## PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS

## ABSTRACT OF THE DISCLOSURE

5 The present invention is directed to compounds of the structural Formula I



- 206T90"20T06209  
50390102-061902  
5
- (a) R1 is selected from the group consisting of hydrogen, substituted or unsubstituted group selected from C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, aryl-C<sub>0-4</sub>-alkyl, heteroaryl-C<sub>0-4</sub>-alkyl, aminoC<sub>1-4</sub>alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkylaryl-C<sub>0-2</sub>-alkyl, arylheteroC<sub>1-8</sub>alkyl, -CHC(O)C<sub>1-4</sub>alkoxy; C<sub>0-4</sub>-alkyl-C(O)heteroC<sub>1-8</sub>alkyl, and -CH<sub>2</sub>-C(O)-R15-R16, wherein R15 is O or NH and R16 is optionally substituted benzyl;
- (b) R2 is selected from the group consisting of substituted or unsubstituted group selected from C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, aryl-C<sub>0-4</sub>-alkyl, heteroaryl-C<sub>0-4</sub>-alkyl, aminoC<sub>1-4</sub>alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkylaryl-C<sub>0-2</sub>-alkyl, arylheteroC<sub>1-8</sub>alkyl, C<sub>0-4</sub>-alkyl-C(O)heteroC<sub>1-8</sub>alkyl, and -CH<sub>2</sub>-C(O)-R15-R16, wherein R15 is O or NH and R16 is optionally substituted benzyl;
- 20
- 25

- 5
- (c) R1 and R2 together may form a substituted or unsubstituted heterocyclic ring;
- (d) E is selected from the group consisting of C(R3)(R4)A, and a substituted or unsubstituted selected from the group consisting of  $(CH_2)_n$  COOR13, aryl-C<sub>0-4</sub>-alkyl, thio-C<sub>1-4</sub>-alkyl, thioaryl, C<sub>1-4</sub>alkoxyaryl, C<sub>1-4</sub>alkoxyC<sub>1-4</sub>alkyl, aminoaryl, and aminoC<sub>1-4</sub>alkyl;
- 10
- (e) n and m are each independently selected from the group consisting of 0, 1, 2 and 3;
- (f) A is an functional group selected from the group consisting of  $(CH_2)_m$  COOR14, C<sub>1-3</sub>alkylnitrile, carboxamide, substituted or unsubstituted sulfonamide, substituted or unsubstituted acylsulfonamide and substituted or unsubstituted tetrazole;
- 5
- (g) R3 is H, saturated or unsaturated C<sub>1-5</sub> alkyl, C<sub>1-5</sub> alkoxy;
- 20
- (h) R4 is H, halo, a substituted or unsubstituted group selected from C<sub>1-5</sub> alkyl, C<sub>1-5</sub> alkoxy, C<sub>3-6</sub> cycloalkyl, aryl C<sub>0-4</sub> alkyl, C<sub>1-4</sub>alkoxyaryl, and phenyl, or R3 and R4 are combined to form a C<sub>3-6</sub> cycloalkyl;
- 25
- (i) R5 and R6 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted group selected from C<sub>1-8</sub> alkyl, aryl-C<sub>0-4</sub>-alkyl, heteroaryl-C<sub>0-4</sub>-alkyl, C<sub>3-6</sub> cycloalkylaryl-
- 30

C<sub>0-2</sub>-alkyl, C<sub>3-6</sub> cycloalkyl-C<sub>0-2</sub>-alkyl, and  
-CH<sub>2</sub>-C(O)-R<sub>17</sub>-R<sub>18</sub>;

(j) R<sub>17</sub> and R<sub>18</sub> are each independently selected  
from C<sub>1-8</sub> alkyl, aryl-C<sub>0-4</sub>-alkyl,  
heteroaryl-C<sub>0-4</sub>-alkyl, C<sub>3-6</sub> cycloalkylaryl-  
C<sub>0-2</sub>-alkyl, and C<sub>3-6</sub> cycloalkyl-C<sub>0-2</sub>-alkyl;

(k) R<sub>13</sub> and R<sub>14</sub> are each independently selected  
from the group consisting of hydrogen,  
optionally substituted C<sub>1-4</sub>alkyl and  
optionally substituted arylmethyl; and  
pharmaceutically acceptable salts thereof.

20250901 20100609

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☒ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: \_\_\_\_\_**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**